Amsterdam UMC Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations Bradbury, Angela R.; Brewer, Carole; Buecher, Bruno; Buys, Saundra S.; Caldes, Trinidad; Caliebe, Almuth; Caligo, Maria A.; Campbell, Ian; Caputo, Sandrine; Chiquette, Jocelyne; Chung, Wendy K.; Claes, Kathleen B. M.; Cook, Jackie; Davidson, Rosemarie; de la Hoya, Miguel; de Leeneer, Kim; de Pauw, Antoine; Delnatte, Capucine; Diez, Orland; Ding, Yuan Chun; Ditsch, Nina; Domchek, Susan M.; Dorfling, Cecilia M.; Velazquez, Carolina; Dworniczak, Bernd; Eason, Jacqueline; Easton, Douglas F.; Eeles, Ros; Ehrencrona, Hans; Ejlertsen, Bent; Engel, Christoph; Engert, Stefanie; Evans, D. Gareth; Faivre, Laurence; Feliubadaló, Lidia; Ferrer, Sandra Fert; Foretova, Lenka; Fowler, Jeffrey; Frost, Debra; Galvão, Henrique C. R.; Ganz, Patricia A.; Garber, Judy; Gauthier-Villars, Marion; Gehrig, Andrea; Gerdes, Anne-Marie; Gesta, Paul; Giannini, Giuseppe; Giraud, Sophie; Glendon, Gord; Godwin, Andrew K.; Greene, Mark H.; Gronwald, Jacek; Gutierrez-Barrera, Angelica; Hahnen, Eric; Hauke, Jan; Henderson, Alex; Hentschel, Julia; Hogervorst, Frans B. L.; Honisch, Ellen; Imyanitov, Evgeny N.; Isaacs, Claudine; Izatt, Louise; Izquierdo, Angel; Jakubowska, Anna; James, Paul; Janavicius, Ramunas; Jensen, Uffe Birk; John, Esther M.; Joseph, Vijai; Kaczmarek, Katarzyna; Karlan, Beth Y.; Kast, Karin; Investigators, kConFab; Kim, Sung-Won; Konstantopoulou, Irene; Korach, Jacob; Laitman, Yael; Lasa, Adriana; Lasset, Christine; Lázaro, Conxi; Lee, Annette; Lee, Min Hyuk; Lester, Jenny; Lesueur, Fabienne; Liljegren, Annelie; Lindor, Noralane M.; Longy, Michel; Loud, Jennifer T.; Lu, Karen H.; Lubinski, Jan; Machackova, Eva; Manoukian, Siranoush; Mari, Véronique; MartínezBouzas, Cristina; Matrai, Zoltan; Mebirouk, Noura; Meindl, Alfons; Mensenkamp, Arjen R.; Mickys, Ugnius; Miller, Austin; Montagna, Marco; Moysich, Kirsten B.; Mulligan, Anna Marie; Musinsky, Jacob; Neuhausen, Susan L.; Nevanlinna, Heli; Ngeow, Joanne; Nguyen, Huu Phuc; Niederacher, Dieter; Nielsen, Henriette Roed; Nielsen, Finn Cilius; Nussbaum, Robert L.; Offit, Kenneth; Öfverholm, Anna; Ong, Kai-Ren; Osorio, Ana; Papi, Laura; Papp, Janos; Pasini, Barbara; Pedersen, Inge Sokilde; MSc, Ana Peixoto; MSc, Nina Peruga; Peterlongo, Paolo; Pohl, Esther; Ba, Nisha Pradhan; Prajzendanc, Karolina; Prieur, Fabienne; Pujol, Pascal; Radice, Paolo; Ramus, Susan J.; Rantala, Johanna; Rashid, Muhammad Usman; Rhiem, Kerstin; Robson, Mark; Rodriguez, Gustavo C.; Rogers, Mark T.; Rudaitis, Vilius; Schmidt, Ane Y.; Schmutzler, Rita Katharina; Senter, Leigha; Shah, Payal D.; Sharma, Priyanka; Side, Lucy E.; Simard, Jacques; Singer, Christian F.; Skytte, Anne-Bine; Slavin, Thomas P.; Snape, Katie; Sobol, Hagay; Southey, Melissa; Steele, Linda; Steinemann, Doris; Sukiennicki, Grzegorz; Sutter, Christian; Szabo, Csilla I.; Tan, Yen Y.; Teixeira, Manuel R.; Terry, Mary Beth; Teulé, Alex; Thomas, Abigail; Thull, Darcy L.; Tischkowitz, Marc; Tognazzo, Silvia; Toland, Amanda Ewart; Topka, Sabine; Trainer, Alison H.; Tung, Nadine; van Asperen, Christi J.; van der Hout, Annemieke H.; van der Kolk, Lizet E.; van der Luijt, Rob B.; van Heetvelde, Mattias; Varesco, Liliana; Varon-Mateeva, Raymonda; Vega, Ana; VillarrealGarza, Cynthia; von Wachenfeldt, Anna; Walker, Lisa; Wang-Gohrke, Shan; Wappenschmidt, Barbara; Weber, Bernhard H. F.; Yannoukakos, Drakoulis; Yoon, Sook-Yee; Zanzottera, Cristina; Zidan, Jamal; Zorn, Kristin K.; Selkirk, Christina G. Hutten; Hulick, Peter J.; Chenevix-Trench, Georgia; Spurdle, Amanda B.; Antoniou, Antonis C.; Nathanson, Katherine L.; EMBRACE Published in: Human mutation DOI: 10.1002/humu.23406 Published: 01/05/2018 Document Version Publisher's PDF, also known as Version of record Document license CC BY Link to publication Citation for pulished version (APA): Bradbury, A. R., Brewer, C., Buecher, B., Buys, S. S., Caldes, T., Caliebe, A., Caligo, M. A., Campbell, I., Caputo, S., Chiquette, J., Chung, W. K., Claes, K. B. M., Cook, J., Davidson, R., de la Hoya, M., de Leeneer, K., de Pauw, A., Delnatte, C., Diez, O., ... EMBRACE (2018). Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. Human mutation, 39(5), 593-620. https://doi.org/10.1002/humu.23406 General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Amsterdam UMC Medical Library know, stating your reasons. In case of a legitimate complaint, the Medical Library will make the material inaccessible and/or remove it from the website. Contact address: outputregistratie@amsterdamumc.nl Download date: 11. Oct. 2026 Received: 30 October 2017 Revised: 9 January 2018 Accepted: 19 January 2018 DOI: 10.1002/humu.23406 SPECIAL ARTICLE Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations Timothy R. Rebbeck1 Dezheng Huo4 Tara M. Friebel1 Ava Kwong5 Angela R. Solano7 TL Chan11 Edith Olah6 Soo-Hwang Teo8 Fergus J. Couch12 Edenir Inêz Palmero14 Rensburg19 Cora M. Aalfs22 Mads Thomassen9 Sue Kyung Park15,16,17 Norbert Arnold30 Banu K. Arun31 Jacopo Azzollini33 Judith Balmaña34 Amie M. Blanco41 Simona Agata25 Irene L. Andrulis28,29 Adalgeir Arason36 Leo Auerbach32 Monica Barile35 Rosa B. Barkardottir36 Andreas Berger39 Raanan Berger40 Kathleen R. Blazer10 Marinus J. Blok42 Valérie Bonadona43 Angela R. Bradbury44 Trinidad Caldes48 Ian Campbell51 Sandrine M. Caputo46 Kathleen B.M. Claes54 Carole Brewer45 Almuth Caliebe49 Kim De Leeneer54 Yuan Chun Ding60 Carolina Velazquez62 Jacqueline Eason64 Douglas F. Easton20 Laurence Faivre71 Lenka Foretova74 Jeffrey Fowler75 Patricia A. Ganz77 Judy Garber78 GEMO Study Collaborators80,81 Capucine Delnatte58 Susan M. Domchek44 Bernd Dworniczak63 Ros Eeles65 Hans Ehrencrona66 Stefanie Engert69 Lidia Feliubadaló72 Debra Frost20 Sandra Fert Ferrer73 Henrique C. R. Galvão76 Anne-Marie Gerdes82 Sophie Giraud85 Mark H. Greene88 Jacek Gronwald89 Frans B.L. Hogervorst94 Antoine de Pauw46 Marion Gauthier-Villars46 Giuseppe Giannini84 HEBON91 Wendy K. Chung53 Rosemarie Davidson57 Christoph Engel68 D. Gareth Evans70 Maria A. Caligo50 Jackie Cook56 Nina Ditsch61 Cecilia M. Dorfling19 EMBRACE20 Bruno Buecher46 Jocelyne Chiquette52 J. Margriet Collée55 Miguel de la Hoya48 Human Mutation. 2018;39:593–620. Elizabeth J. van Goska Leslie20 Ella Asseryanis32 Saundra S. Buys47 Jan Hauke90 Diana Torres3,18 Javier Benitez37,38 Bernardo Bonanni35 Bent Ejlertsen67 Torben A. Kruse9 Julian Adlard24 Lesley Andrews27 Daniel Barrowdale20 Jeffrey N. Weitzel10 Michael T. Parsons21 Julio Abugattas23 Kristiina Aittomäki26 Ute Hamann3 Olufunmilayo I. Olopade4 David E. Goldgar13 Lesley McGuffog20 Orland Diez59 Eitan Friedman2 Gord Glendon86 Paul Gesta83 Andrew K. Godwin87 Angelica Gutierrez-Barrera31 Alex Henderson92 Ellen Honisch95 Andrea Gehrig79 Eric Hahnen90 Julia Hentschel93 Evgeny N. Imyanitov96 wileyonlinelibrary.com/journal/humu Claudine Isaacs97 c 2018 Wiley Periodicals, Inc.  593 REBBECK ET AL . Louise Izatt98 Angel Izquierdo99 Anna Jakubowska89 Paul James100 Ramunas Janavicius101 Uffe Birk Jensen102 Esther M. John103,104 Katarzyna Kaczmarek89 Beth Y. Karlan106 Karin Kast107 KConFab Investigators108 Sung-Won Kim109 Joseph Vijai105 Irene Konstantopoulou110 Jacob Korach111 Yael Laitman2 Adriana Lasa112 Christine Lasset43 Conxi Lázaro72 Annette Lee113 Min Hyuk Lee114 Jenny Lester106 Fabienne Lesueur115 Annelie Liljegren116 Jennifer T. Loud119 Karen H. Lu120 Siranoush Manoukian33 Noralane M. Lindor117 Jan Lubinski89 Véronique Mari121 Zoltan Matrai123 Noura Mebirouk115 Alfons Meindl69 Arjen R. Mensenkamp125 Michel Longy118 Eva Machackova74 Cristina Martínez-Bouzas122 Hanne E.J. Meijers-Heijboer124 Ugnius Mickys126 Austin Miller127 Marco Montagna25 Kirsten B. Moysich128 Anna Marie Mulligan129 Jacob Musinsky105 Susan L. Neuhausen60 Heli Nevanlinna130 Huu Phuc Nguyen132 Dieter Niederacher95 Finn Cilius Nielsen133 Robert L. Nussbaum134 Anna Öfverholm136 Kai-ren Ong137 Barbara Pasini140 Joanne Ngeow131 Henriette Roed Nielsen9 Kenneth Offit135 Ana Osorio138 Inge Sokilde Pedersen141 Laura Papi139 Ana Peixoto142,143 Paolo Peterlongo144 Esther Pohl90 Nisha Pradhan105 Fabienne Prieur145 Pascal Pujol146 Paolo Radice147 Johanna Rantala150 Muhammad Usman Rashid3,151 Mark Robson152 Gustavo C. Rodriguez153 Ane Y. Schmidt133 Rita Katharina Schmutzler90 Janos Papp6 Nina Peruga89 Karolina Prajzendanc89 Susan J. Ramus148,149 Kerstin Rhiem90 Mark T. Rogers154 Vilius Rudaitis155 Leigha Senter156 Priyanka Sharma157 Lucy E. Side158 Anne-Bine Skytte102 Thomas P. Slavin10 Katie Snape160 Melissa Southey161,162 Linda Steele60 Doris Steinemann163 Grzegorz Sukiennicki89 Christian Sutter164 Csilla I. Szabo165 Yen Y. Tan39 Manuel R. Teixeira142,143 Mary Beth Terry166 Alex Teulé167 Abigail Thomas168 Darcy L. Thull169 Marc Tischkowitz170 Sabine Topka105 Alison H Trainer172 Annemieke H. van der Hout175 Mattias Van Heetvelde54 Ana Vega180 Lisa Walker184 Jacques Simard159 Payal D. Shah44 Silvia Tognazzo25 Nadine Tung173 Lizet E. van der Kolk176 Liliana Varesco178 Cynthia Villarreal-Garza181,182 Shan Wang-Gohrke185 Bernhard H. F. Weber186 Cristina Zanzottera33 Hagay Sobol161 Amanda Ewart Toland171 Christi J. van Asperen174 Rob B. van der Luijt177 Raymonda Varon-Mateeva179 Anna von Wachenfeldt183 Barbara Wappenschmidt90 Drakoulis Yannoukakos110 Jamal Zidan187 Christian F. Singer32 Sook-Yee Yoon8 Kristin K. Zorn188 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 594 Christina G. Hutten Selkirk189 Amanda B. Spurdle21 Peter J. Hulick190 Antonis C. Antoniou20 Georgia Chenevix-Trench21 Katherine L. Nathanson44 1 Harvard TH Chan School of Public Health and Dana Farber Cancer Institute, Boston, USA 2 The Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, Chaim Sheba Medical Center, Ramat Gan 52621, and the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel 3 Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany 4 Center for Clinical Cancer Genetics and Global Health, University of Chicago, Chicago, USA 5 The Hong Kong Hereditary Breast Cancer Family Registry, Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong, China 6 Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary 7 INBIOMED, Faculty of Medicine, University of Buenos Aires/CONICET and CEMIC, Department of Clinical Chemistry, Medical Direction, Buenos Aires, Argentina 8 Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia 9 Department of Clinical Genetics, Odense University Hospital, Odense, Denmark 10 Division of Clinical Cancer Genomics, City of Hope Cancer Center, California, USA 11 Division of Molecular Pathology, Department of Pathology, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong 12 Department of Laboratory Medicine and Pathology, and Health Sciences Research, Rochester, USA 13 Department of Dermatology, University of Utah School of Medicine, Salt Lake City, USA 14 Molecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, Brazil 15 Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea 16 Department of Biomedical Science, Seoul National University Graduate School, Seoul, Korea 17 Cancer Research Center, Seoul National University, Seoul, Korea 18 Institute of Human Genetics, Pontificia Universidad Javeriana, Colombia 19 Cancer Genetics Laboratory, Department of Genetics, University of Pretoria, South Africa 20 Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK 21 Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia 22 Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands 23 City of Hope Clinical Cancer Genomics Community Research Network, Duarte, USA 24 Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK 25 Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy 26 Department of Clinical Genetics, Helsinki University Hospital, Helsinki, Finland 27 Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, Australia 28 Lunenfeld-Tanenbaum Research Institute, Toronto, Canada 29 Department of Molecular Genetics, University of Toronto, Toronto, Canada 30 Department of Gynaecology & Oncology, Medical University of Vienna, Austria 31 Department of Breast Medical Oncology and Clinical Cancer Genetics Program, University Of Texas MD Anderson Cancer Center, Houston, USA 32 Dept of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria 33 Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Instituto Nazionale Tumori (INT), Milan, Italy 34 Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain 35 Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Milan, Italy 36 Laboratory of Cell Biology, Department of Pathology, hus 9, Landspitali-LSH v/Hringbraut, 101 Reykjavik, Iceland and BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik, Iceland 37 Human Genetics Group and Genotyping Unit (CEGEN), Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain 38 Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain 39 Dept of OB/GYN, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria 40 The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel 41 UCSF Cancer Genetics and Prevention Program, San Francisco, USA 42 Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands 43 Unité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, 28 rue Laënnec, Lyon, France 44 Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA 45 Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter, UK 46 Service de Génétique, Institut Curie, 26 rue d'Ulm, Paris, France 47 Department of Medicine, Huntsman Cancer Institute, Salt Lake City, USA 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 595 REBBECK ET AL . REBBECK ET AL . 48 Molecular Oncology Laboratory, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain 49 Institute of Human Genetics, University Hospital of Schleswig-Holstein, Kiel, Germany 50 Section of Molecular Genetics, Dept. of Laboratory Medicine, University Hospital of Pisa, Pisa, Italy 51 Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia 52 CRCHU de Quebec-oncologie, Centre des maladies du sein Deschênes-Fabia, Hôpital du Saint-Sacrement, Sainte-Foy, Canada 53 Departments of Pediatrics and Medicine, Columbia University, New York, USA 54 Center for Medical Genetics, Ghent University, Gent, Belgium 55 Department of Clinical Genetics, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands 56 Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK 57 Department of Clinical Genetics, South Glasgow University Hospitals, Glasgow, UK 58 Unité d'oncogénétique, ICO-Centre René Gauducheau, Saint Herblain, France 59 Oncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Clinical and Molecular Genetics Area, Vall d'Hebron University Hospital, Barcelona, Spain 60 Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, USA 61 Department of Gynaecology and Obstetrics, Ludwig-Maximilian University, Munich, Germany 62 Cáncer Hereditario, Instituto de Biología y Genética Molecular, IBGM, Universidad de Valladolid, Valladolid, Spain 63 Institute of Human Genetics, University of Münster, Münster, Germany 64 Nottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, Nottingham, UK 65 Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK 66 Department of Clinical Genetics, Lund University Hospital, Lund, Sweden 67 Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark 68 Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany 69 Department of Gynaecology and Obstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical University, Munich, Germany 70 Genomic Medicine, Manchester Academic Health Sciences Centre, Division of Evolution and Genomic Sciences, University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK 71 Centre de Lutte Contre le Cancer Georges François Leclerc, France and Genomic and Immunotherapy Medical Institute, Dijon University Hospital, Dijon, France 72 Molecular Diagnostic Unit, Hereditary Cancer Program, ICO-IDIBELL (Catalan Institute of Oncology-Bellvitge Biomedical Research Institute), Barcelona, Spain 73 Laboratoire de Génétique Chromosomique, Hôtel Dieu Centre Hospitalier, Chambéry, France 74 Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic 75 Columbus Cancer Council, Ohio State University, Columbus, USA 76 Oncogenetics Department, Barretos Cancer Hospital, Barretos, Brazil 77 UCLA Schools of Medicine and Public Health, Division of Cancer Prevention & Control Research, Jonsson Comprehensive Cancer Center, Los Angeles, USA 78 Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, USA 79 Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics, University of Würzburg, Germany, Würzburg 80 Department of Tumour Biology, Institut Curie, Paris, France 81 Institut Curie, Paris, France 82 Department of Clinical Genetics, Copenhagen, Denmark 83 Service Régional Oncogénétique Poitou-Charentes, Centre Hospitalier, Niort, France 84 Department of Molecular Medicine, University La Sapienza, and Istituto Pasteur - Fondazione Cenci-Bolognetti, Rome, Italy 85 Bâtiment Cheney D, Centre Léon Bérard, Lyon, France 86 Ontario Cancer Genetics Network: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada 87 Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, USA 88 Clinical Genetics Branch, DCEG, NCI, NIH, Bethesda, USA 89 Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland 90 Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany 91 The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Netherlands Cancer Institute, Amsterdam, The Netherlands 92 Institute of Genetic Medicine, Centre for Life, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK 93 Institute of Human Genetics, University Leipzig, Leipzig, Germany 94 Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands 95 Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany 96 N.N. Petrov Institute of Oncology, St. Petersburg, Russia 97 Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA 98 Clinical Genetics, Guy's and St. Thomas’ NHS Foundation Trust, London, UK 99 Genetic Counseling Unit, Hereditary Cancer Program, IDIBGI (Institut d'Investigació Biomèdica de Girona), Catalan Institute of Oncology, Girona, Spain 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 596 597 100 Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Australia 101 Hematology, oncology and transfusion medicine center, Dept. of Molecular and Regenerative Medicine, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania 102 Department of Clinical Genetics, Aarhus University Hospital, Aarhus N, Denmark 103 Department of Epidemiology, Cancer Prevention Institute of California, Fremont, USA 104 Department of Health Research and Policy (Epidemiology) and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA 105 Clinical Genetics Research Laboratory, Dept. of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA 106 Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA 107 Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Dresden, Germany 108 Research Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia and The Sir Peter MacCallum Department of Oncology University of Melbourne, Parkville, Australia 109 Department of Surgery, Daerim St. Mary's Hospital, Seoul, Korea 110 Molecular Diagnostics Laboratory, INRASTES (Institute of Nuclear and Radiological Sciences and Technology), National Centre for Scientific Research “Demokritos”, Athens, Greece 111 The Gyneco-Oncology Department, Chaim Sheba Medical Center, Ramat Gan, Israel 112 Servicio de Genética-CIBERER U705, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain 113 The Feinstein Institute for Medical Research, Manhasset, USA 114 Department of Surgery, Soonchunhyang University and Seoul Hospital, Seoul, Korea 115 Inserm U900, Institut Curie, PSL Research University, Paris, France 116 Department of Oncology Radiumhemmet and Institution of Oncology and Patology, Karolinska University Hospital and Karolinska Institutet, Solna, Sweden 117 Department of Health Sciences Research, Mayo Clinic, Scottsdale, USA 118 Oncogénétique, Institut Bergonié, Bordeaux, France 119 Clinical Genetics Branch, DCEG, NCI, NIH, Bethesda, USA 120 Department of Gynecological Oncology and Clinical Cancer Genetics Program, University Of Texas MD Anderson Cancer Center, Houston, USA 121 Centre Antoine Lacassagne, Nice, France 122 Laboratorio de Genética Molecular, Servicio de Genética, Hospital Universitario Cruces, BioCruces Health Research Institute, Barakaldo, Spain 123 Department of Surgery, National Institute of Oncology, Budapest, Hungary 124 Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands 125 Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands 126 Vilnius university Santariskiu hospitalNational Center of Pathology, Vilnius, Lithuania 127 NRG Oncology, Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, USA 128 Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, USA 129 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada 130 Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, HUS, Finland 131 Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre Singapore, Bukit Merah, Singapore 132 Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany 133 Center for Genomic Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark 134 Cancer Genetics and Prevention Program, University of California San Francisco, San Francisco, USA 135 Clinical Genetics Research Laboratory, Dept. of Medicine, Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, USA 136 Department of Clinical Genetics, Sahlgrenska University Hospital, Gothenburg, Sweden 137 West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare NHS Trust, Edgbaston, UK 138 Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain 139 Unit of Medical Genetics, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy 140 Department of Medical Sciences, University of Turin, Turin, Italy 141 Section of Molecular Diagnostics, Department of Biochemistry, Aalborg University Hospital, Aalborg, Denmark 142 Department of Genetics, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal 143 Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal 144 IFOM, The FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy 145 Service de Génétique Clinique Chromosomique et Moléculaire, Hôpital Nord, St Etienne, France 146 Unité d'Oncogénétique, CHU Arnaud de Villeneuve, Montpellier, France 147 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico), Isti- tuto Nazionale Tumori (INT), Milan, Italy 148 School of Women's and Children's Health, UNSW, Sydney, Australia 149 The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License REBBECK ET AL . REBBECK ET AL . 150 Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden 151 Department of Basic Sciences, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan 152 Clinical Genetics Services, Dept. of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA 153 Division of Gynecologic Oncology, North Shore University Health System, University of Chicago, Evanston, USA 154 All Wales Medical Genetics Services, University Hospital of Wales, Cardiff, UK 155 Department of Gynecology, Vilnius University Hospital Santariskiu Clinics, Centre of Woman's Health and pathology, Vilnius, Lithuania 156 Clinical Cancer Genetics Program, Division of Human Genetics, Department of Internal Medicine, The Comprehensive Cancer Center, The Ohio State University, Columbus, USA 157 Department of Internal Medicine, Division of Oncology, University of Kansas Medical Center, Westwood, USA 158 North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Trust, London, UK 159 Genomics Center, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec City, Canada 160 Medical Genetics Unit, University of London, St George's, UK 161 Département Oncologie Génétique, Prévention et Dépistage, Institut Paoli-Calmettes, Marseille Medical School-AM University, Marseille, France 162 Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Parkville, Australia 163 Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany 164 Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany 165 National Human Genome Research Institute, National Institutes of Health, Bethesda, USA 166 Department of Epidemiology, Columbia University, New York, USA 167 Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL (Bellvitge Biomedical Research Institute), Catalan Institute of Oncology, CIBERONC, Gran Via de l'Hospitalet, Barcelona, Spain 168 Department of Health Sciences Research, Mayo Clinic, Rochester, USA 169 Department of Medicine, Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, USA 170 Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montreal, Canada 171 Division of Human Genetics, Departments of Internal Medicine and Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, USA 172 Parkville Familial Cancer Centre, Royal Melbourne Hospital, Melbourne, Australia 173 Department of Medical Oncology, Beth Israel Deaconess Medical Center, Massachusetts, USA 174 Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands 175 Department of Genetics, University Medical Center, Groningen University, Groningen, The Netherlands 176 Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands 177 Department of Medical Genetics, University Medical Center, Utrecht, The Netherlands 178 Unit of Hereditary Cancer, Department of Epidemiology, Prevention and Special Functions, IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy 179 Institute of Human Genetics, Campus Virchov Klinikum, Berlin, Germany 180 Fundación Pública Galega de Medicina Xenómica-SERGAS, Grupo de Medicina Xenómica-USC, CIBERER, IDIS, Santiago de Compostela, Spain 181 Departamento de Investigacion y de Tumores Mamarios del, Instituto Nacional de Cancerologia, Mexico City, Mexico 182 Centro de Cancer de Mama del Hospital Zambrano HellionTecnologico de Monterrey, San Pedro Garza Garcia, Mexico 183 Department of Oncology, Karolinska University Hospital, Stockholm, Sweden 184 Oxford Regional Genetics Service, Churchill Hospital, Oxford, UK 185 Department of Gynaecology and Obstetrics, University Hospital, Ulm, Germany 186 Institute of Human Genetics, Regensburg University, Regensburg, Germany 187 Institute of Oncology, Rivka Ziv Medical Center, Zefat, Israel 188 Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, USA 189 Center for Medical Genetics, North Shore University Health System, Evanston, USA 190 Medical Director, Center for Medical Genetics, NorthShore University HealthSystem, Clinical Assistant Professor of Medicine, University of Chicago Pritzker School of Medicine, Evanston, USA 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 598 Correspondence Timothy R. Rebbeck, PhD, 1101 Dana, 450 Brookline Avenue, Dana Farber Cancer Institute, Boston, MA 02215, USA. Email: Timothy_Rebbeck@dfci.harvard.edu Funding information National Institutes of Health, Grant/Award Number: R01-CA102776 United States NIH, including NCI, funding supported the research presented in this manuscript. Communicated by Stephen J. Chanock Abstract The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained from 69 centers in 49 countries on six continents. This study comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. We observed substantial variation in mutation type and frequency by geographical region and race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and which could be used in targeted (panel) first pass genotyping for specific populations. Knowledge of the population-specific mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for genetic testing and may justify a more broad-based oncogenetic testing in some populations. KEYWORDS BRCA1, BRCA2, breast cancer, ethnicity, geography, mutation, ovarian cancer 1 INTRODUCTION 0.1 to 0.7%, respectively (Peto et al., 1999; Struewing et al., 1997; Whittemore et al., 2004). The Australian Lifepool study, studying a Women who carry germline mutations in either BRCA1 [MIM# control population consisting of cancer-free women ascertained via 113705] or BRCA2 [MIM# 600185] are at an increased risk of breast population-based mammographic screening program, estimated the and ovarian cancers. Estimates of cancer risk associated with BRCA1 overall frequency of BRCA1 and BRCA2 mutations to be 0.65% (1:153), and BRCA2 mutations vary depending on the population studied. For with BRCA1 mutations at 0.20% (1:500) and BRCA2 mutations at 0.45% mutations in BRCA1, the estimated average risk of breast and ovar- (1:222) (Thompson et al., 2016). Estimates from the Exome Aggrega- ian cancers ranges from 57 to 65% and 20 to 50%, respectively (Chen tion Consortium (ExAC) are similar, with frequencies of BRCA1 and & Parmigiani, 2007; Kuchenbaecker et al., 2017). For BRCA2, average BRCA2 mutations (excluding The Cancer Genome Atlas [TCGA] data) at risk estimates range from 35 to 57% and 5 to 23%, respectively (Chen 0.21% (1:480) and 0.31% (1:327), respectively; or combined at 0.51% & Parmigiani, 2007; Kuchenbaecker et al., 2017). Mutation-specific (1:195) (Maxwell, Domchek, Nathanson, & Robson, 2016). As they do cancer risks have been reported that suggest breast cancer cluster not include large genomic rearrangements, some newer population- regions (BCCR) and ovarian cancer cluster regions (OCCR) exist in both based estimates may still underrepresent the total number of BRCA1 BRCA1 and BRCA2 (Gayther et al., 1997; Kuchenbaecker et al., 2017; and BRCA2 mutations. Although the overall prevalence of BRCA1 and Rebbeck et al., 2015). The identification of mutations in BRCA1 or BRCA2 mutations in most general populations is low, many hundreds of BRCA2 has important clinical implications, as knowledge of their pres- thousands of yet-to-be-tested individuals worldwide carry these muta- ence is important for risk assessment and informs medical manage- tions. ment for patients. Interventions, such as risk-reducing bilateral mas- The prevalence of founder mutations in some racial/ethnic groups tectomy and salpingo-oophorectomy or annual breast magnetic res- is much higher. For example, the mutations BRCA1 c.5266dup onance imaging (MRI) screening, are available to women who carry (5382insC), BRCA1 c.68_69del (185delAG) and BRCA2 c.5946del deleterious BRCA1 or BRCA2 mutations to enable early detection of (6174delT) have a combined prevalence of 2–3% in U.S. Ashkenazi breast cancer and for active risk reduction by risk-reducing surgery Jews (Roa, Boyd, Volcik, & Richards, 1996; Struewing et al., 1997; Whit- (Domchek et al., 2010; Rebbeck et al., 2002; Saslow et al., 2007). temore et al., 2004). For these mutations, double heterozygotes in The presence of BRCA1 or BRCA2 mutations can also influence can- BRCA1 and BRCA2 also have been reported (Friedman et al., 1998; cer treatment decisions, principally around the use of platinum agents Moslehi et al., 2000; Ramus et al., 1997a; Rebbeck et al., 2016). Several or poly(ADP-ribose) polymerase (PARP) inhibitors (Lord & Ashworth, other founder mutations have been identified, including the Icelandic 2017) or contralateral risk-reducing mastectomy. Increased numbers founder mutation BRCA2 c.771_775del (999del5) (Thorlacius et al., of women are having clinical genetic testing for BRCA1 and BRCA2 1996), the French Canadian mutations BRCA1 c.4327C > T (C4446T), mutations, and recommendations continue to expand to whom testing the BRCA2 c.8537_8538del (8765delAG) (Oros et al., 2006b; Tonin should be offered (NCCN, 2017). et al., 2001; Tonin, Mes-Masson, Narod, Ghadirian, & Provencher, In Whites drawn from the general populations in North America 1999), the BRCA1 mutations c.181T > G, and c.4034del in Central- and the United Kingdom, the prevalence of BRCA1 and BRCA2 muta- Eastern Europe (Gorski et al., 2000), the BRCA1 c.548-?−4185+?del tions has been estimated around a broad range from 0.1 to 0.3% and in Mexico (Villarreal-Garza et al., 2015b; Weitzel et al., 2013), 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 599 REBBECK ET AL . REBBECK ET AL . the BRCA2 mutation c.9097dup in Hungary (Ramus et al., 1997b; Van individuals with both BRCA1 and BRCA2 mutations), one of the two Der Looij, et al., 2000), and others. These mutations represent the mutations was chosen at random for inclusion in the analysis. majority of mutations observed in these populations and have been The CIMBA data set was used to describe the distribution of confirmed as true founder mutations as they have common ances- mutations by effect and function. For the remaining analyses, muta- tral haplotypes (Neuhausen et al., 1996, 1998; Oros et al., 2006a). tions were excluded if self-reported race/ethnicity data were miss- Recurrent mutations have been identified in other populations, but ing. Pathogenicity of mutation was defined as follows: (1) generating they represent a smaller proportion of all unique BRCA1 and BRCA2 a premature termination codon (PTC), except variants generating a mutations, and have not been characterized as true founder muta- PTC after codon 1854 in BRCA1 and after codon 3309 of BRCA2, (2) tions. There are multiple recurrent mutations in Scandinavian, Dutch, large in-frame deletions that span one or more exons, and (3) dele- French, and Italian populations (Ferla et al., 2007). Similarly, a number tion of transcription regulatory regions (promoter and/or first exon) of recurrent mutations specific to non-European populations also have expected to cause lack of expression of mutant allele. We also included been reported in Hispanic/Mexican, African American, Middle East- missense variants considered pathogenic by using multifactorial likeli- ern, and Asian populations (Bu et al., 2016; Ferla et al., 2007; Kurian, hood approaches (Bernstein et al., 2006; Goldgar et al., 2004). Muta- 2010; Lang et al., 2017; Ossa & Torres, 2016; Villarreal-Garza et al., tions that did not meet the above criteria but have been classified 2015b). as pathogenic by Myriad Genetics, Inc. (Salt Lake City, UT) also were The mutational spectra in BRCA1 and BRCA2 are best delineated included. Classification of nonsense-mediated decay (NMD) was based in Whites from Europe and North America. However, data on muta- on in-silico predictions and was not based on molecular classification tional spectra in non-White populations of Asian, African, Mediter- (Anczukow et al., 2008). ranean, South American and Mexican Hispanic descent have also been Contingency table analysis using a chi-square test was used to test reported (Abugattas et al., 2015; Ahn et al., 2007; Alemar et al., 2016; for differences in dichotomous variables, as was a t-test for continu- Bu et al., 2016; Eachkoti et al., 2007; Ferla et al., 2007; Gao et al., 2000; ous variables. Mutation counts are presented as the number of fami- Gonzalez-Hormazabal et al., 2011; Ho et al., 2000; Jara et al., 2006; lies with the mutation. Fisher's exact tests were used if sample sizes in John et al., 2007; Kurian, 2010; Laitman et al., 2011; Lang et al., 2017; any contingency table cell were less than five. Analyses were done in Lee et al., 2003; Li, et al., 2006; Nanda et al., 2005; Ossa & Torres, 2016; STATA, v. 14.2. Pal, Permuth-Wey, Holtje, & Sutphen, 2004; Rodríguez et al., 2012; Seong et al., 2009; Sharifah et al., 2010; Solano et al., 2017; Song et al., 2005; Song et al., 2006; Toh et al., 2008; Torres et al., 2007; Troudi et al., 3 RESULTS 2007; Villarreal-Garza et al., 2015b; Vogel et al., 2007; Weitzel et al., 2005; Weitzel et al., 2007; Zhang et al., 2009). In the current study, we 3.1 provide a global description of BRCA1 and BRCA2 mutations by geog- Mutations in BRCA1 and BRCA2 raphy and race/ethnicity from the investigators of the Consortium of From the 26,861 BRCA1 and 16,954 BRCA2 mutation carriers in Investigators of Modifiers of BRCA1/2 (CIMBA). the CIMBA data set as of June 2017, 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations were studied to count only one occurrence of a mutation per family. Figure 1 shows the countries that contributed mutations to this report. 2 METHODS From among these families, 1,650 unique BRCA1 and 1,731 unique BRCA2 mutations were identified. The unique mutations and num- Details of centers participating in CIMBA and data collection proto- ber of families in which each mutation was observed are listed in cols have been reported previously (Antoniou et al., 2007). Details Supporting Information Table S1. In each gene, the five most com- of the CIMBA initiative and information about the participating cen- mon mutations (including founder mutations) accounted for 33% of ters can be found at http://cimba.ccge.medschl.cam.ac.uk/ (Chenevix- all mutations in BRCA1 (8,739 of 26,861 mutation carriers) and 19% Trench et al., 2007). All included mutation carriers participated in clini- of all mutations in BRCA2 (3,244 of 16,954 mutation carriers). A cal or research studies at the host institutions after providing informed website containing information about the most common mutations consent under IRB-approved protocols. Sixty-nine centers and mul- reported here can be found at: http://cimba.ccge.medschl.cam.ac.uk/. ticenter consortia submitted data that met the CIMBA inclusion cri- This information may be periodically updated as new data become teria (Antoniou et al., 2007). Only female carriers with pathogenic available. BRCA1 and/or BRCA2 mutations were included in the current analysis. One mutation carrier per family in the CIMBA database was included in this report. The actual family relationships (e.g., pedigrees) 3.2 Mutation type and effect were not available, but a variable that defined family membership sup- Table 1 presents a summary of the type of BRCA1 or BRCA2 muta- plied by each center was used for this purpose. Less than 1% of fami- tions and their predicted effect on transcription and translation. The lies (86 of 29,700) had two family members with two different muta- most common mutation type was frameshift followed by nonsense. The tions. In these situations, each mutation observed in the family was most common effect of BRCA1 and BRCA2 mutations was premature included in the analysis. In the case of the 94 dual mutation carriers (i.e., translation termination and most of the mutant mRNAs were predicted 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 600 F I G U R E 1 Countries (in red) that provided data on BRCA1 and/or BRCA2 mutation carriers in this report. Race/ethnic breakdown is reported for countries with more than 100 observations with multiple ethnicities totaling at least 10% of the country's sample (i.e., Australia, Brazil, Canada, USA) to undergo nonsense-mediated mRNA decay (Anczukow et al., 2008). CIMBA centers that ascertained these patients, but these patients Despite having the same spectrum of mutations in BRCA1 and BRCA2, originated from a different country. Based on such small numbers, it the frequency distribution by mutation type, effect, or function dif- was impossible to make inferences about the relative importance of fered significantly (p < .05) between BRCA1 and BRCA2 mutation car- mutations in these locations. A description of the major ethnicity by riers for many groups, as shown in Table 1. These observed differences country is provided in Supporting Information Table S2. are largely because genomic rearrangements and missense mutations The mutational distribution among the major racial/ethnic groups account for a much higher proportion of mutations in BRCA1 when and by geography is summarized in Tables 4 and 5. Table 4 includes only compared with BRCA2, as previously described (Welcsh & King, 2001). those individuals for whom self-identified race/ethnicity was recorded. We and others have found that BCCR and OCCR exist that may Note that in some countries it is prohibited to collect data on race and confer differential cancer risks (Gayther et al., 1997; Gayther et al., ethnicity, so this information is missing. Among the 10 most common 1995; Kuchenbaecker et al., 2017; Rebbeck et al., 2015). Figure 2 BRCA1 mutations in each racial/ethnic group, a few were seen in sev- reports the relative frequency of mutations in the BCCR and OCCR eral populations, including the recurrent Jewish and Eastern European by race/ethnicity. Compared with Whites, we observed differences in founder mutations c.5266dup (5382insC) and c.68_69del (185delAG), the relative frequency of mutations in the BRCA1 BCCR and OCCR c.815_824dup in African Americans and Hispanics, c.3756_3759del in in Asians and Hispanics, and in the BRCA2 OCCR in Hispanics. To the White and Jewish individuals, and c.5503C > T and c.3770_3771del degree that the mutations within the BCCRs and OCCRs conferred in Asians and Jews. Similarly, recurrent mutations in BRCA2 included differential cancer risks, these data suggest that BRCA1 and BRCA2 c.5946del (6174delT) in Whites and Jews, c.2808_2811del in Whites, mutation-associated cancer risks may vary by race/ethnicity. African Americans, Asians, Hispanics, and Jews, c.6275_6276del in Whites and Hispanics, c.3847_3848del in Whites and Jews, c.658_659del in African Americans and Hispanics, and c.3264dup in 3.3 Geography and race/ethnicity Hispanics and Jews. The majority of other recurrent BRCA1 and BRCA2 The most common mutations by country are summarized in Table 2 mutations were only observed within a single racial/ethnic group, par- (BRCA1) and Table 3 (BRCA2). The locations of the mutations that ticularly African Americans, Asians, and Hispanics. Of note, the vast were observed in African American, Asian, and Hispanic populations majority of women who self-identified as Jewish carry the Ashke- are depicted in Figure 3 (BRCA1) and Figure 4 (BRCA2). Some coun- nazi Jewish founder mutations BRCA1 c.5266dup and c.68_69del and tries (Albania, Bosnia, Costa Rica, Ireland, Honduras, Japan, Norway, BRCA2 c.5946del. Only 72 (3.9%) of 1,852 BRCA1 mutation carrier Peru, Philippines, Qatar, Saudi Arabia, Romania, Venezuela and Turkey) families and 55 (5.6%) of 990 BRCA2 mutation carrier families who contributed fewer than 10 mutation carriers to the CIMBA database. self-identified as being Jewish carried other (nonfounder) mutations. Many of these mutations were submitted to the central database by However, since many individuals of self-identified Jewish ancestry are 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 601 REBBECK ET AL . TA B L E 1 REBBECK ET AL . Characteristics of BRCA1 and BRCA2 mutations in the CIMBA database (by unique mutation) Mutation Type Mutation Function Mutation Class (N = 1,650) BRCA2 (N = 1,731) N % N Designation Definition % p-value Large Deletion (DL) Genomic DNA deletion (encompassing at least 1 exon) 130 7.9 34 1.9 <.0001 Large Duplication (DP) Genomic DNA duplication (encompassing at least 1 exon) 27 1.6 11 0.6 .010 Frameshift (FS) Deletion or insertion resulting in a disruption of the open reading frame 948 57.5 1,141 65.9 <.0001 In-Frame Deletion (IFD) Small deletions, splice site mutations or large genomic rearrangements that result in a change in the mRNA but do not change the open reading frame 1 <0.1 2 0.1 .518 Missense (MS) Results in an altered amino acid 46 2.8 13 0.8 .0001 Nonsense (NS) Point mutation resulting in a stop codon 313 19.0 380 22.0 .027 Splice (SP) Results in aberrant RNA splicing 166 10.1 131 7.6 .013 20 1.1 19 1.1 1.00 Multiple Types (including those listed above) Mutation Effect BRCA1 No RNA Mutation is predicted to abrogate RNA production 21 1.3 6 0.3 .003 Premature Termination Codon (PTC) Result of a nonsense substitution, frameshift due to small deletion or insertion, aberrant splicing, or large genomic rearrangement 1,331 81.0 1,542 89.0 <.0001 Unknown/Other Unknown effect 298 18.0 183 10.6 <.0001 Nonsense-Mediated Decay (NMD)a (Anczukow et al., 2008) Mutation is predicted to result in reduced transcript level due to decay of RNA and/or degradation/instability of truncated proteins 1,213 73.9 1,523 88.0 <.0001 No NMD Mutations generating a premature stop codon in the first or last exon that is predicted not to result in NMD 58 3.5 16 0.9 <.0001 No RNA Loss of expression due to deletion of promoter and/or transcription start site 21 1.3 6 0.4 .003 Re-Initiation Mutations presumed to result in translation re-initiation but produce unstable protein 4 0.2 0 0.0 .294 NMD/Re-initiation Mutations presumed to result in translation re-initiation but produce unstable protein 60 3.7 0 0.0 – Unknown/Other Unknown function 294 17.8 187 10.7 <.0001 1 Mutations predicted to be associated with unstable or no protein 1,298 78.6 1,529 88.3 <.0001 2 Mutations predicted to be associated with stable mutant proteins 112 6.8 36 2.1 <.0001 3 Unknown function 240 14.6 167 9.6 <.0001 P-values reflect the comparison of frequencies between BRCA1 and BRCA2 mutation carriers. a References (Anczukow et al., 2008; Buisson, et al., 2006; Mikaelsdottir, et al., 2004; Perrin-Vidoz, et al., 2002; Ware, et al., 2006) only tested for the three founder mutations, this number is likely to be Mexican Americans, perhaps as a reflection of the complex continen- underestimated. tal admixture of this population (Villarreal-Garza et al., 2015b). BRCA1 In African Americans, the majority of BRCA1 mutations were not c.390C > A and c.5496_5506delinsA were most commonly found in the observed in any other racial/ethnic group, implying these mutations Asian population. In BRCA2, c.2808_2811del was found among the 10 may be of African origin. In Hispanics, the most common BRCA1 muta- most frequent mutations in all races/ethnicities. tions also were observed among individuals from other regions who did not self-identify as Hispanic, including BRCA1 c.3331_3334del (also observed in Australia, Europe, USA, and the UK), and BRCA1 3.4 Recurrent mutations c.68_69del (the Jewish founder mutation) (Weitzel et al., 2005, 2013). As expected, the most common mutations in the entire data set The BRCA1 c.815_824dup mutation has been reported as being of were the founder mutations BRCA1 c.5266dup (5382insC), BRCA1 African origin, but has also been reported as a recurrent mutation in c.68_69del (185delAG), and BRCA2 c.5946del (6174delT). In part, the 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 602 F I G U R E 2 Proportion of mutations in the breast cancer cluster regions (BCCR) and ovarian cancer cluster region (OCCR) in BRCA1 and BRCA2 by ethnicity as defined previously (Rebbeck et al., 2015). Asterisk indicates proportion is significantly different than Caucasian proportion (p-value < 0.05) high frequency of these mutations is a consequence of panels that facil- tions included BRCA1 c.4327C > T and BRCA2 c.8537_8538del in itate testing for these three mutations in women of Jewish descent. Quebec. This latter mutation in BRCA2 also is the most common muta- However, these two BRCA1 mutations also are relatively common in tion in high-risk families in Sardinia (Pisano et al., 2000) and was regions with a low proportion of individuals who self-identify as Jew- also reported in a few Jewish Yemenite families, with a distinct hap- ish (e.g., Hungary, Czech Republic, France, Germany, Italy, Poland Spain, lotype(Palomba et al., 2007). The BRCA1 c.181T > G mutation was Russia, and UK). BRCA1 c.5266dup is a founder mutation thought to observed in Central Europe (Austria, Czech Republic, Germany, Hun- have originated 1800 years ago in Scandinavia/Northern Russia, enter- gary, Italy and Poland), but also observed in the US, Argentina, Latvia, ing the Ashkenazi-Jewish population 400–500 years ago, and thus has Lithuania and Israel. This mutation has been found on a common haplo- origins and a spread pattern independent of the Ashkenazim (Hamel type in individuals of Polish and Ashkenazi Jewish ancestry, suggesting et al., 2011). Haplotype studies have been used to determine the origin it is an Eastern European founder mutation (Kaufman, Laitman, Gron- of BRCA1 c.68_69del in populations not considered to have a high pro- wald, Lubinski, & Friedman, 2009). The large rearrangement muta- portion of Jewish ancestry. In some populations, such as the Hispan- tion in BRCA1 c.548-?_4185+?del (ex9-12del) appears to be an impor- ics in the USA and Latin American, it is associated with the Ashkenazi tant founder mutation in Mexico, with findings of a common haplotype Jewish haplotype, presumably due to unrecognized (Jewish) ances- and an estimated age at 74 generations (∼1,500 years) (Weitzel et al., try (Ah Mew, Hamel, Galvez, Al-Saffar, & Foulkes, 2002; Velez et al., 2013). 2012; Weitzel et al., 2005). In other populations, such as Pakistani We observed a number of other recurrent mutations. BRCA1 and Malaysians, where BRCA1 c.68_69del is a recurrent mutation, it c.3331_3334del comprised more than half of all mutations identified appears to have arisen independently, as it is carried on a distinct hap- in Colombia, consistent with a previous report that this is a founder lotype (Kadalmani et al., 2007; Rashid et al., 2006). A different haplo- mutation in the Colombian population (Torres et al., 2007). However, type was also reported for several British families (the ‘Yorkshire hap- this mutation has not been found at high rates in a second Colombian lotype’) that is distinct from both the Jewish and the Indian-Pakistani population (Cock-Rada, et al., 2017). BRCA2 c.2808_2811del was fre- haplotypes (Laitman et al., 2013; Neuhausen et al., 1996). quently observed, not only as the most common mutation in France The only locations in which these three founder mutations were not and Colombia, but also in other Western and Southern European commonly observed were Belgium and Iceland. Iceland has another countries, and destinations to which individuals from these countries founder mutation (i.e., BRCA2 c.771_775del). Yet other founder muta- have migrated. It estimated to have arisen approximately 80 (46–134) 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 603 REBBECK ET AL . 28 Singapore 166 Belgium 208 235 Greece Hungary 100 223 782 Lithuania Netherlands 126 21 9 254 2 1 47 41 381 418 31 101 42 1 41 115 1 173 1 18 45 47 61 7 45 16 15 Unique mutations c.5406+1_5406+3del(4) c.181T > G(2) c.2635G > T(4) c.2934T > G(13) c.68_69del (4) c. 3770_3771del(8) c.2635G > T(5) c.5503C > T(11) c.5333-36_5406+ 400del(87) c.4035del(112) c.5266dup(49) c.5266dup(124) c.547+1G > T(1) c.5074G > A(3) c.5266dup(78) c.5266dup(47) c.5266dup(411) c.5266dup(118) c.3485del(8) c.2475del(91) c.5266dup(87) c.4158_4162del(1) c.2359dup(40) c.181T > G(51) c.4225C > T (1) c.68_69del(56) c.3333del(1) c 5266dup(4) c.4097-2A > G (5) c.2685_2686del(60) c.5277+1G > A(66) c.2197_2201del(41) c.3756_3759del(1) c.1687C > T(5) c.181T > G(5) c.4035del(40) c.181T > G221) c.1687C > T(39) c.5266dup(58) c.181T > G(44) c.5278-?_5406+?del(5) c.5468-285_5592+ 4019del insCACAG(23) (Continues) c.5266dup(40) c.5177_5180del(4) c.4675G > A(1) c.1380dup(37) c.5251C > T(4) c.5251C > T(13) c.3481_3491del(55) c.3839_3843delins AGGC (40) c.4327C > T(49) c.1687C > T(62) c.4327C > T(3) c.5213G > A(30) c.3756_3759del(6) c.3841C > T(9) c.962G > A(17) c.5503C > T(16) c.3214del(1) c.2269del(1) c.3770_3771del(3) c.3627dup(8) c.981_982del(1) c.3342_3345del(4) c.3228_3229del(4) c.4122_4123del(1) 5 c.1687C > (T42) c.3710del(39) c.1687C > T(16) c.3607C > T(10) c.1687C > T(26) c.190T > C(43) c.68_69del(22) c.181T > G(60) c.427G > T(1) c.4689C > G(63) c.5406+644_*8273del(24) c.181T > G(196) c.5212G > A(29) c.68_69del(63) c.5266dup(41) c.3319G > T(81) c.3481_3491del(70) c.181T > G(20) c.3661G > T(12) c.3700_3704del(25) c.3018_3021del(35) c.212+3A > G(26) c.3756_3759del (22) c.213-12A > G(1) c.2635G > T(2) c.4065_4068del (23) c.66dup(6) c.4148C > G(3) c.5030_5033del(9) c.4508C > A(8) c.470_471del(3) c.922_924delinsT(11) c.5266dup(46) c.5266dup(45) c.2617dup(2) c.5496_5506delinsA(17) c.390C > A(19) c.2726dup(9) c.5266dup(151) c.68_69del(4) c.4240dup(1) c.4372C > T(5) c.68_69del(510) c.470_471del(7) c.3268C > T(2) c.1374del(4) c.191G > A(2) c.5266dup(7) c.303T > G(4) 4 c.2641G >T(18) 3 2 1 REBBECK ET AL . 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License Latvia 1,120 Italy 2 2,287 Germany Ireland 1,522 France 3 57 Iceland 667 Denmark Finland 1 208 Czech Rep. Bosnia 391 Austria Europe 1 Albania 581 Australia Australia Europe 1 93 Turkey 72 Malaysia Pakistan 158 Korea 70 679 Israel Hong Kong South Africa Asia 20 49 Nigeria Africa Families Country Five most common mutations (number observed) Common BRCA1 mutations by country of origin (by family) Conti-nent TA B L E 2 604 450 1 1 Venezuela 25 Mexico Peru 55 101 89 4,219 Colombia Brazil Argentina USA Canada 10 1 1 15 2 39 35 613 112 297 108 181 c.5123C > A(1) c.4986+6T > C(1) c.548-?_4185+?del(8) c.3331_3334del(36) c.5266dup(31) c.68_69del(22) c.68_69del(1130) c.68_69del(99) c.68_69del(2) c.5123C > A(19) c.3331_3334del(18) c.5266dup(12) c.5026_5027del(1) c.824_825ins10(2) c.5030_5033del(1) c.1687C > T(4) c.211A > G(2) c.427G > T(3) c.3916_3917del(3) c.181T > G(6) c.135-?_441+?del(4) c.211A > G(11) c.3756_3759(49) c.3756_3759del(12) c.5266dup(60) c.5266dup(19) c.3331_3334del(23) c.4185+2T > C(1) c.5266dup(2) c.4065_4068del(58) c.2834_2836delinsC(16) c.3756_3759del(62) c.1082_1092del(26) c.3770_3771del(23) 5 c.68_69del(2) c.3756_3759del(113) c.5266dup(50) c.4327C > T(66) c.5266dup(554) c.4186-?_4357+?dup (78) c.2475del(27) c.1687C > T(31) c.68_69del(134) c.4065_4068del(104) c.68_69del(62) c.3048_3052dup(68) c.5123C > A(61) c.4035del(11) c.211A > G(78) c.68_69del(7) c.21A > G(2) c.2037delinsCC(7) c.3817C > T(3) 4 c.5333-36_5406+400del(3) 3 c.4035del(69) 2 c.181T > G(276) c.5266dup(135) c.5266dup(1) c.3331_3334del(15) c.5266dup(711) 1 Five most common mutations (number observed) 605 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License South/ Central America 438 Sweden 1,389 678 UK 160 Russia 1 Spain 23 49 Portugal Romania 1 8 1,064 Poland Unique mutations Families Country (Continued) North America Conti-nent TA B L E 2 REBBECK ET AL . 1 Saudi Arabia 52 997 Finland France 9 242 706 493 167 11 1 c.5645C > A(1) c.5722_5723del(2) c.6275_6276del(38) c.5946del(25) c.8067T > A(26) c.7180A > T(29) c.6580dup(1) c.6468_6469del(31) c. 7913_7917del(4) c.9097dup(2) c.2808_2811del(29) c.9026_9030del(22) c.771_775del(7) c.3847_3848del(4) c.8878C > T(33) c.658_659del(13) c.5576_5579del(1) c.771_775del(89) c.8951C > G(1) c.5946del(11) c.7976G > A(3) c.9097dup(17) c.3847_3848del(34) c.1813dup(51) c.5946del(27) c.7480C > T(12) c.9118-2A > G(18) c.2808_2811del(34) c.6373del(44) c.7617+1G > A(61) c.1310_1313del (25) c.1389_1390del(9) c.2808_2811del(4) c.8904del(14) c.5645C > A(4) c.7913_7917del(5) c.8537_8538del(12) c.6275_6276del(17) c.5909C > A(19) c.9672dupA(23) c.6410del(1) c.5682C > G(25) c. 5213_5216del (21) (Continues) c.7879A > T(1) c.8247_8248delGA(18) c.5722_5723del(2) c.9403del(3) c.9501+1G > A(2) c.6656C > G(3) c.5682C > G(23) c.8364G > A(22) c.5946del(29) c.1286T > G(2) c.3847_3848del(16) c.9403del(4) c.3847_3848del(7) c.7846del(6) c.3487_3848del(10) c.956dup(1) c.2990T > G(1) c.809C > G(2) c.6724_6725del(6) c.6024dup(1) c.9294C > G(4) c.6939del(1) c.994del(1) 5 c.8327T > G(2) c.6486_6489del(25) c.1813dup(8) c.516+1G > T(16) c.5682C > G(10) c.7977-1G > C(11) c.3860del(11) c.6275_6276del(25) c.8755-1G > A(15) c.8915del(1) c.8961_8964del(1) c.8364G > A(17) c.2808_2811del(1) c.5073dup(3) c.3109C > T(3) c.92G > A(1) c.2808_2811del(3) c.8754+1G > T(1) c.6468_6469del(1) c.5576_5579del(14) c.3847_3848del(1) c.7007G > T(4) c.5213_5216del(1) c.2402_2412del(1) 4 c.1399A > T(16) c.3744_3747del(18) c.4936_4939del(2) c.7878G > A(5) c.6944_6947del(2) c.5241_5242insTA(1) 3 c.5946del(53) c.200_1910-877dup(1) c.473C > A(1) c.7977-1G > C(1) c.2023del(1) c.5222_5225del(3) c.262_263del(8) c.7480C > T(40) c.8537_8538del(5) c.2808_2811del(5) c.3109C > T(22) c.5946del(330) c.5946del(6) c.8817_8820delA(2) 2 c.7934del(80) c.1310_1313del(3) 1 Five most frequently observed mutations (number observed) REBBECK ET AL . 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License Netherlands Lithuania 26 2 Ireland Italy 2 89 Iceland 22 39 28 81 Hungary 367 375 16 101 42 39 87 178 10 1 1 1 17 47 93 1 5 45 18 Greece 1,109 442 Denmark Germany 81 116 Czech Republic. Belgium 496 185 Australia Austria Europe 10 1 Qatar Singapore 1 Philippines 64 19 Pakistan Korea Malaysia 1 220 Japan 91 339 Israel Hong Kong 103 12 Families Australia Asia Nigeria Africa South Africa Country Unique mutations Frequently observed BRCA2 mutations by country of origin (by family) Conti-nent TA B L E 3 606 311 19 1 1 6 Costa Rica Honduras Mexico 47 Colombia 49 Brazil 3,064 Argentina USA Canada 6 1 1 4 33 21 626 108 308 68 217 3 1 22 20 1 Unique mutations c.1796_1800del(6) c.3264dup (1) c.7558C > T(1) c.9235del(1) c.6275_6276del (1) c.5851_5854del (2) c.2808_2811del(4) c.2808_2811del(15) c.2808_2811del(5) c.2T > G(5) c.2808_2811del(86) c.5946del(45) c.3847_3848del(6) c.9026_9030del(2) c.2224C > T (1) c.6275_6276del(1) c.5542del (1) c.93G > A(1) c.6405_6409del(3) c.6037A > T(4) c.156_157insAlu(4) c.658_659del(50) c.6275_6276del(11) c.755_758del(36) c.1813dup(62) c.2808_2811del(13) c.4478_4481del(37) c.2830A > T(7) c.5946del(66) c.9026_9030del(52) c.6275_6276del(32) c.682-2A > C(2) c.9382C > T(3) c.5946del(1) c.9294C > A(1) 4 c. 7913_7917del(1) 3 c.2808_2811del(56) c.5410_5411del(1) c.9097dup(5) c.8946del(2) 2 c.5946del(18) c.5946del(742) c.8537_8538del(48) c.6275_6276del(107) c.4258del(11) c.3264dup(58) c.3682_3685del(1) c.9097dup(1) c.156_157insAlu(39) c.5946del(3) c.771_775del(2) 1 Five most frequently observed mutations (number observed) c.6502G > T (1) c.1138del(2) c.5645C > G(2) c.6275_6276del(49) c.5857G > T(10) c.5682C > G(33) c.7558C > T(5) c.9018C > A(16) c.5645G > A(2) c.635_636del(1) 5 607 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License South/ Central America 123 1,200 Sweden UK 3 670 1 Romania Russia 71 Portugal Spain 2 23 Norway Poland Families Country (Continued) North America Conti-nent TA B L E 3 REBBECK ET AL . REBBECK ET AL . F I G U R E 3 BRCA1 mutation distribution in African American, Asian, and Hispanic. Length of mutation indicator reflects the number of observed mutations. Domains are zinc/ring finger (green); BRCT domain (red); BRCT (C terminus) (blue). Mutation type is indicated for each mutation by color: green: missense mutations; black: truncating mutations (nonsense, nonstop, frameshift deletion, frameshift insertion, splice site, in-frame mutations); purple: all other types of mutations generations ago. However, due to the diversity of the haplotypes, mul- understanding of the mutation distribution in specific populations as tiple independent origins could not be ruled out (Neuhausen et al., well as imparting clinical and biological implications for our under- 1998). BRCA2 c.6275_6276del was a recurrent BRCA2 mutation in standing of BRCA1- and BRCA2-associated carcinogenesis. Australia, the UK, Belgium, Spain, the Netherlands, and North America. Clinical testing for BRCA1 and BRCA2 mutations has benefited sub- This mutation has been estimated to have originated 52 (24–98) gen- stantially from knowledge about common mutations in specific popu- erations ago from a single founder (Neuhausen et al., 1998). Recurrent lations. In many countries, the three Ashkenazi-Jewish founder muta- or founder mutations were observed in diverse populations. For exam- tions are offered as a mutation testing panel for self-reported Ashke- ple, the c.115T > G (Cys39Gly) mutation has been described in Green- nazim, based on their frequency. This approach is much less expensive landers (Hansen et al., 2009). The c.2641G>T and c.7934del muta- than comprehensive gene sequencing. The identification of commonly- tions have both been reported as founder mutation in South African occurring mutations in other populations could lead to more efficient Afrikaners (Reeves et al., 2004). and cost-effective mutation testing for BRCA1 and BRCA2. For example, Villareal-Garza et al. (2015a) have developed the HISPANEL of mutations that optimizes testing in Hispanic/Latino populations. In the present study, we have identified mutations that may exist at a 4 DISCUSSION sufficient prevalence to warrant consideration for population-specific mutation testing panels. Criteria for developing such panels for BRCA1 We have reported worldwide distribution of BRCA1 and BRCA2 muta- and BRCA2 mutation screening are not available. However, muta- tions curated in the CIMBA dataset. These results may aid in the tions that are in a specific population and that capture a sufficient 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 608 F I G U R E 4 BRCA2 mutation distribution in African American, Asian, and Hispanic CIMBA sample (per family). Length of mutation indicator reflects the number of observed mutations. Domains are BRCA repeats (green); BRCA helica (red); OB binding domain (blue); tower (yellow) and OB3 binding domain (purple). Mutation type is indicated for each mutation by color: green: missense mutations; black: truncating mutations (nonsense, nonstop, frameshift deletion, frameshift insertion, splice site, in-frame mutations); purple: all other types of mutations percentage of mutations in high risk individuals and families in that study of these populations or races/ethnicities; the data reflect pat- population may be appropriate for use in targeted genetic testing. terns of recruitment (e.g., individuals with higher risk or prior diagno- Before such panels can be developed, population-based studies of sis of cancer who consented to participate in research protocols) that mutation frequency in specific populations should be undertaken. The contributed to the CIMBA consortium. Certain racial/ethnic or socio- data reported herein provide a list of the recurrent mutations around demographic groups are under- or overrepresented or missing in our which such panels could be developed, but the frequencies are not data set and, as a consequence, mutations may be over- or underrepre- population based, particularly in settings where founder mutations sented. For example, the existence of a commercial panel of three Jew- are preferentially screened (e.g., the Jewish founder panels). Similarly, ish founder mutations enhances genetic testing for those mutations. As putative founder mutations identified by assessing common ancestral a result, the most frequently observed mutations in some populations origins of specific mutations (rather than just high prevalence; Table 5) (e.g., the United States) reflect the widespread use of this testing panel may form the basis of population-specific BRCA1 and BRCA2 mutation in the US population. Similar arguments may also apply for other popu- screening panels. lations, where testing for certain founder mutations may be more fre- We report the distribution of BRCA1 and BRCA2 mutations in quent. Therefore, the relative frequencies of mutations by population nearly 30,000 families of bona-fide disease-associated mutations. The in the present study may be subject to such testing biases. Comparing strengths of this report include the large sample size that reflects a the relative frequencies is also complicated by the inclusion of related geographically and racially/ethnically diverse set of BRCA1 and BRCA2 individuals. mutation carriers. However, some limitations need to be considered. Second, although the CIMBA data represent most regions First, the sample set presented here does not reflect a systematic around the world, there are limitations related to which groups of 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 609 REBBECK ET AL . c.2635G > T(2%) c.2726dup(2%) c.3627dup(2%) c.68_69del(3%) c.5467+1G > A(3%) c.182G > A(3%) c.5251C > T(2%) c.4484G > T(2%) c.68_69del(6%) c.4035del(2%) c.4065_4068del(2%) c.3756_3759del(2%) c.1687C > T(2%) c.4327C > T(2%) c.2475del(2%) c.4186-?_4357+?dup(1%) 3 4 5 6 7 8 9 10 c.3847_3848del(2%) c.5682C > G(2%) c.1813dup(2%) c.8537_8538del(1%) c.658_659del(1%) c.7934del(1%) 5 6 7 8 9 10 7,156 c.771_775del(2%) 4 1,242 c.2808_2811del(3%) 3 Unique Mutations c.6405_6409del(3%) c.6275_6276del(3%) 2 c.145G > T(5%) c.9026_9030del(3%) c.3744_3747del(4%) c.1399A > T(3%) c.9382C > T(5%) 125 77 248 538 c.5164_5165del(1%) c.7133C > G(1%) c.6531_6534del(2%) c.7024C > T(2%) c.3922G > T(3%) 91 207 c.6275_6276del(2%) c.9699_9702del(2%) c.1813dup(2%) c.7878G > A(2%) c.262_263del(2%) c.5542del(3%) c.2808_2811del(2%) c.2957_2958insG(2%) c.658_659del(3%) c.1310_1313del(4%) c.658_659del(3%) c.2808_2811del(9%) c.5576_5579del(3%) c.3264dup(17%) c.7480C > T(8%) c.3109C > T(6%) c.2808_2811del(6%) c.4552del(6%) 104 408 c.4327C > T(2%) c.3029_3030del(3%) c.1960A > T(3%) c.2433del(3%) 240 550 c.3770_3771del(2%) c.815_824del(3%) c.211A > G(5%) 44 990 c.3264dup(0.1%) c.9207T > A(0.1%) c.5238del(0.2%) c.4829_4830del (0.2%) c.2808_2811del (0.2%) c.5621_5624del (0.2%) c.9382C > T(0.3%) c.1754del(0.4%) c.3847_3848del (0.4%) c.5946del(94%) 56 1,852 c.4936del(0.1%) c.3770_3771del (0.1%) c.4689C > G(0.1%) c.4185+1G > T(0.1%) 753 2,551 c.658_659del(1%) c.9672dup(1%) c.5682C > G(1%) c.3847_3848del(2%) c.1310_1313del(2%) c.5645C > A(2%) c.1813dup(3%) c.2808_2811del(3%) c.6275_6276del(4%) c.5946del(5%) 765 4,583 c.4327C > T(1%) c.2685_2686del(68%) c.5277+1G > A (2%) c.4065_4068del(2%) c.3481_3491del(2%) c.1687C > T (2%) c.2934T > G(0.2%) c.5333-36_5406+400del(3%) c.181T > G(5%) c.5503C > T(0.1%) c.1757del(0.3%) c.3756_3759del (0.3%) c.5123C > A(9%) c.548-?_4185+?del(7%) c.68_69del(17%) c.5266dup(12%) Other REBBECK ET AL . 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License Families c.5616_5620del(4%) c.5946del(5%) 1 BRCA2 174 77 11,258 1,206 Unique Mutations c.922_924delinsT(2%) c.190T > G(3%) c.68_69del(2%) c.470_471del(3%) c.5503C > T(2%) c.5177_5180del(5%) c.4357+1G > A(5%) c.5266dup(24%) c.68_69del(72%) Jewish c.3331_3334del(10%) c.68_69del(12%) c.390C > A(4%) c.5496_5506delinsA (3%) c.815_824dup(16%) c.5324T > G (7%) c.181T > G (6%) Hispanic/Latino Asian c.5266dup(17%) African American 2 Caucasian 1 Mutation rank Ten most frequently observed mutations by self-identified race/ethnicity (%) (by family) Families BRCA1 TA B L E 4 610 North America c.3847_3848del(3%) c.658_659del(2%) c.9382C > T(1%) c.3264dup(1%) c.55073dup(1%) 6 7 8 9 10 3,375 c.6275_6276del(2%) 5 27 c.1813dup(2%) 4 660 c.8537_8538del(2%) 3 Unique Mutations c.2808_2811del(3%) 2 c.7934del(47%) 187 170 c.5042_5043del(1%) c.6393del(1%) c.5213_5216del(1%) c.8817_8820del(1%) c.6944_6947del(1%) c.1310_1313del(2%) c.5946del(4%) 1,100 c.2808_2811del(1%) 58 976 1,315 222 c.5645C > A(1%) 179 10,175 c.9026_9030del(1%) c.7180A > T(1%) c.5851_5854del (1%) c.8537_8538del(1%) c.7878G > A(1%) c.5682C > G(1%) c.5645C > G(1%) c.1310_1313del(1%) c.1813dup(1%) c.3847_3848del(1%) c.771_775del(1%) c.2808_2811del(2%) c.5946del(2%) c.6275_6276del(2%) 1282 11,748 c.3770_3704del(1%) c.3756_3759del(1%) c.2475del(1%) c.658_659del(1%) c.262_263del(1%) c.4065_4068del(2%) c.3481_3491del(1%) c.6405_6409del(3%) c.6037A > T(2%) c.5576_5579del(2%) c.1399A > T(2%) c.2T > G(2%) c.156_157insAlu (2%) c.3109C > T(3%) c.3744_3747del(2%) c.2808_2811del (11%) c.5946del(9%) c.5946del(34%) 75 271 c.7480C > T(4%) 187 c.5030_5033del (2%) c.135-?_441+?del(2%) c.1687C > T(2%) c.548-?_4183+8?del(3%) c.181T > G(3%) c.1687C > T(2%) c.4035del(2%) 1,047 c.250C > T(1%) c.8297del(1%) c.4478_4481del(1%) c.755_758del(1%) c.2808_2811del(1%) c.3847_3848del(1%) c.5682C > G(1%) c.7977-1G > C(1%) c.6275_6276del(2%) c.5946del(5%) 173 581 c.1961del(2%) c.70_80del(2%) c.5278-?_5592+?del (2%) c.4327C > T(2%) c.4186-?_4357+?dup(3%) c.5503C > T(3%) c.3756_3759del(4%) c.4065_4068del(4%) c.5266dup(8%) c.68_69del(4%) c.181T > G(7%) Australia c.68_69del(10%) Europe c.5266dup(17%) 611 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License Families c.6535_6536insA (1%) c.774_775del(1%) c.5946del(23%) 1 BRCA2 69 30 4,669 654 Unique Mutations c.922_924delinsT(1%) c.1175_1214del(1%) 10 c.470_471del(1%) c.4186-?_4357+?dup(1%) 9 c.2726dup(1%) c.1504_1508del(3%) c.3268C > T(3%) c.1687C > T(1%) 8 c.3770_3771del(1%) c.191G > A(3%) c.4838_4839insC (3%) c.2934T > G(1%) c.303T > G(6%) c.3756_3759del(1%) c.213-11T > G(1%) 6 c.211A > G(5%) 7 c.5123C > A(8%) c.5496_5506delinsA (2%) c.68_69del(9%) c.5266dup(16%) c.5503C > T(1%) c.390C > A(2%) c.5266dup(14%) South/Central America c.3331_3334del (20%) c.3228_3229del(6%) c.68_69del(6%) c.4327C > T(2%) c.4065_4068del(1%) 4 c.1374del(6%) 5 c.5266dup(10%) c.5266dup(13%) c.181T > G(3%) 2 Asia c.68_69del(47%) Africa c.2641G >T(26%) 3 c.68_69del(26%) 1 Mutation rank Ten most frequently observed mutations by continent of ascertainment (%) (by family) Families BRCA1 TA B L E 5 REBBECK ET AL . REBBECK ET AL . individuals have been tested and which centers contributed data. In The data presented herein provide new insights into the world- particular, non-White ancestry populations are still underrepresented wide distribution of BRCA1 and BRCA2 mutations. The identifica- in research reports of mutation spectrum and frequency. Genetic tion of recurrent mutations in some racial/ethnic groups or geo- testing in the developing world remains limited. graphical locations raises the possibility of defining more efficient Third, we presented the mutations in terms of type or effect strategies for genetic testing. Three Jewish founder mutations BRCA1 (Table 1), but these designations are not always based on experimental c.5266dup (5382insC) and BRCA1 c.68_69del (185delAG) and BRCA2 evidence. For example, NMD mutation status is almost always defined c.5946del (6174delT) have long been used as a primary genetic screen- by a prediction rule rather than in vitro experiments that confirm the ing test for women of Jewish descent. The identification here of presence of nonsense mediated decay. other recurrent mutations in specific populations may similarly pro- Fourth, we presented the occurrence of putative founder muta- vide the basis for other mutation-specific panels. For example, BRCA1 tions. Some of these founder mutations (e.g., BRCA1 c.68_69del, BRCA2 c.5266dup (5382insC) may be useful as a single mutation screen- c.771_775del) have been demonstrated to be true founder mutations ing test in Central-Eastern European populations before undertaking based on actual ancestry analyses. Others, however, have only been full sequencing. However, this basic test may be supplemented with identified as occurring commonly in certain populations, but haplotype screening for BRCA1 c.181T > G, as the second most common mutation or similar analyses of founder status may not have been done. of the region, and for some special cases, to include most common Hun- Fifth, our analysis was based on self-reported race/ethnicity of garian BRCA2 founder mutation c.9097dup (9326insA) for those with study participants, but this information may misclassify some groups of Hungarian ancestry (Ramus et al., 1997b; van der Looij et al., 2000). individuals. For example, some Middle Eastern groups may have been In Iceland, only two mutations were reported: the founder mutation classified as “Caucasian” based on the data available, but in fact may BRCA2 c.771_775del and the rarer BRCA1 c.5074G > A (Bergthorsson represent a distinct group that was not captured here. Moreover, in et al., 1998). A number of other situations can be identified in which some large centers participating in CIMBA, collecting information on specific mutations explain a large proportion of the total mutations race/ethnicity is prohibited and these mutation carriers were excluded observed in a population. These and other such examples suggest that from the comparisons. targeted mutation testing panels that include specific mutations could Finally, we evaluated mutations by racial/ethnic and geographic be developed for use in specific populations. Finally, we focused on designations, but some of these may be misclassified. For example, female BRCA1 and BRCA2 mutation carriers in this report. However, while BRCA1 c.68_69del has been shown to arise independently of the the growing knowledge about BRCA1 and BRCA2-associated cancers in Jewish founder mutation in Pakistan (Rashid et al., 2006), we cannot men, particularly prostate cancer (Ostrander & Udler, 2008; Pritchard determine if the identified group also contains some Ashkenazi Jewish et al., 2016), suggests that the information presented herein will also individuals. have value in genetic testing of men. ACKNOWLEDGMENTS Study Funding Acknowledgments CIMBA The CIMBA data management and data analysis were supported by All the families and clinicians who contribute to the studies; Sue Healey, Cancer Research – UK grants C12292/A20861, C12292/A11174. ACA in particular taking on the task of mutation classification with the late is a Cancer Research -UK Senior Cancer Research Fellow. GCT and Olga Sinilnikova; Maggie Angelakos, Judi Maskiell, Gillian Dite, Helen ABS are NHMRC Research Fellows. iCOGS: the European Tsimiklis Community's Seventh Framework Programme under grant agreement n◦ 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer (CRN-87521), and the Ministry of Economic Development, Innovation and Export Trade (PSR-SIIRI-701), Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The PERSPECTIVE project was supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the Ministry of Economy, Science and Innovation through Genome Québec, and The Quebec Breast Cancer Foundation. (Continues) 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 612 BCFR - all This Breast Cancer Family Registry (BCFR) is supported by grant UM1 CA164920 from the USA National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. BCFR-AU Maggie Angelakos, Judi Maskiell, Gillian Dite, Helen Tsimiklis. BCFR-NY We wish to thank members and participants in the New York site of the Breast Cancer Family Registry for their contributions to the study. BCFR-ON We wish to thank members and participants in the Ontario Familial Breast Cancer Registry for their contributions to the study. BFBOCC-LT BFBOCC is partly supported by: Lithuania (BFBOCC-LT): Research Council of Lithuania grant SEN-18/2015 BFBOCC-LT acknowledge Laimonas Griškevičius. BFBOCC-LV acknowledge Drs Janis Eglitis, Anna Krilova and Aivars Stengrevics. BIDMC BIDMC is supported by the Breast Cancer Research Foundation BMBSA BRCA-gene mutations and breast cancer in South African women (BMBSA) was supported by grants from the Cancer Association of South Africa (CANSA) to Elizabeth J. van Rensburg BRICOH SLN was partially supported by the Morris and Horowitz Families Endowed Professorship. CEMIC This work is funded by CONICET and Instituto Nacional del Cancer, Ministerio de Salud de la Nacion Argentina (1995/15) We thank to Florencia Cardoso, Natalia Liria and Pablo Mele in their biospecimen and data management. CNIO CNIO study is partially funded by the Spanish Ministry of Health PI16/00440 supported by FEDER funds, the Spanish Ministry of Economy and Competitiveness (MINECO) SAF2014-57680-R and the Spanish Research Network on Rare diseases (CIBERER) We thank Alicia Barroso, Rosario Alonso and Guillermo Pita for their assistance. COH-CCGCRN City of Hope Clinical Cancer Genomics Community Network and the Hereditary Cancer Research Registry, supported in part by the Breast Cancer Research Foundation, by Award Number RC4CA153828 (PI: J. Weitzel) from the National Cancer Institute and the Office of the Director, National Institutes of Health, and by the National Cancer Institute of the National Institutes of Health under Award Number R25CA171998 (PIs: K. Blazer and J. Weitzel). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health CONSIT TEAM Associazione Italiana Ricerca sul Cancro (AIRC; IG2014 no.15547) to P. Bernard Peissel, Milena Mariani and Daniela Zaffaroni of the Radice; Funds from Italian citizens who allocated the 5 × 1000 share of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Davide their tax payment in support of the Fondazione IRCCS Istituto Bondavalli, Maria Rosaria Calvello and Irene Feroce of the Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic Europeo di Oncologia, Milan, Italy; Alessandra Viel and Riccardo projects ‘5 × 1000′ ) to S Manoukian; Associazione Italiana per la Dolcetti of the CRO Aviano National Cancer Institute, Aviano (PN), Ricerca sul Cancro IG17734; Italian Ministry of University and Italy; Francesca Vignolo-Lutati of the University of Turin, Turin, Italy; Research, PRIN projects; Istituto Pasteur-Fondazione Cenci Bolognetti Gabriele Capone of the University of Florence, Florence, Italy; Laura to G. Giannini; FiorGen Foundation for Pharmacogenomics to L. Papi; Ottini of the “Sapienza” University, Rome, Italy; Viviana Gismondi of Funds from Italian citizens who allocated the 5 × 1000 share of their the IRCCS AOU San Martino – IST, Istituto Nazionale per la Ricerca tax payment in support of the IRCCS AOU San Martino - IST according sul Cancro, Genoa, Italy; Maria Grazia Tibiletti and Daniela Furlan to Italian laws (institutional project) to L. Varesco; Associazione Italiana of the Ospedale di Circolo-Università dell'Insubria, Varese, Italy; Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo Antonella Savarese and Aline Martayan of the Istituto Nazionale Tumori Regina Elena, Rome, Italy; Stefania Tommasi and Brunella Pilato of the Istituto Nazionale Tumori “Giovanni Paolo II” - Bari, Italy, and the personnel of the Cogentech Cancer Genetic Test Laboratory, Milan, Italy. DFCI This research has been supported by R01-CA08534 and R01-CA102776 to TRR._______ DEMOKRITOS This research has been co-financed by the European Union (European Social Fund – ESF) and Greek national funds through the Operational Program “Education and Lifelong Learning” of the National Strategic Reference Framework (NSRF) - Research Funding Program of the General Secretariat for Research & Technology: SYN11_10_19 NBCA. Investing in knowledge society through the European Social Fund.___________________ BMBSA wish to thank the families who contribute to the BMBSA study (Continues) 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 613 REBBECK ET AL . REBBECK ET AL . DKFZ The DKFZ study was supported by the DKFZ and in part by the SKMCH & We thank all participants, clinicians, family doctors, researchers, and RC, Lahore, Pakistan and the Pontificia Universidad Javeriana, Bogota, technicians for their contributions and commitment to the DKFZ Colombia. study and the collaborating groups in Lahore, Pakistan (Noor Muhammad, Sidra Gull, Seerat Bajwa, Faiz Ali Khan, Humaira Naeemi, Saima Faisal, Asif Loya, Mohammed Aasim Yusuf) and Bogota, Colombia (Ignacio Briceno, Fabian Gil). EMBRACE EMBRACE is supported by Cancer Research UK Grants C1287/A10118 RE is supported by NIHR support to the Biomedical Research Centre at and C1287/A11990. D. Gareth Evans and Fiona Lalloo are supported The Institute of Cancer Research and The Royal Marsden NHS by an NIHR grant to the Biomedical Research Centre, Manchester. The Foundation Trust Investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Ros Eeles and Elizabeth Bancroft are supported by Cancer Research UK Grant C5047/A8385. Ros Eeles is also supported by NIHR support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust FCCC The authors acknowledge support from The University of Kansas Cancer We thank Ms. JoEllen Weaver and Dr. Betsy Bove for their technical support. Center (P30 CA168524) and the Kansas Bioscience Authority Eminent Scholar Program. A.K.G. was funded by 5U01CA113916, R01CA140323, and by the Chancellors Distinguished Chair in Biomedical Sciences Professorship. FPGMX This work was partially supported by FISPI05/2275 and Mutua Madrileña Foundation (FMMA). GC-HBOC The German Consortium of Hereditary Breast and Ovarian Cancer The Regensburg HBOC thanks Dr. Ivana Holzhauser and Dr. Ines (GC-HBOC) is supported by the German Cancer Aid (grant no 110837), Schönbuchner for their contributions to the study Rita K. Schmutzler. GEMO The study was supported by the Ligue Nationale Contre le Cancer; the Association “Le cancer du sein, parlons-en!” Award; the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program and the French National Institute of Cancer (INCa). We would like to thank Marta Santamariña, Ana Blanco, Miguel Aguado, Uxía Esperón and Belinda Rodríguez for their contribution with the study. Genetic Modifiers of Cancer Risk in BRCA1 or BRCA2 Mutation Carriers (GEMO) study: National Cancer Genetics Network «UNICANCER Genetic Group», France. We wish to pay a tribute to Olga M. Sinilnikova, who with Dominique Stoppa-Lyonnet initiated and coordinated GEMO until she sadly passed away on the 30th June 2014, and to thank all the GEMO collaborating groups for their contribution to this study. GEMO Collaborating Centers are: Coordinating Centres, Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon - Centre Léon Bérard, & Equipe «Génétique du cancer du sein», Centre de Recherche en Cancérologie de Lyon: Olga Sinilnikova†, Sylvie Mazoyer, Francesca Damiola, Laure Barjhoux, Carole Verny-Pierre, Mélanie Léone, Nadia Boutry-Kryza, Alain Calender, Sophie Giraud; and Service de Génétique Oncologique, Institut Curie, Paris: Claude Houdayer, Etienne Rouleau, Lisa Golmard, Agnès Collet, Virginie Moncoutier, Muriel Belotti, Camille Elan, Catherine Nogues, Emmanuelle Fourme, Anne-Marie Birot. Institut Gustave Roussy, Villejuif: Brigitte Bressac-de-Paillerets, Olivier Caron, Marine Guillaud-Bataille. Centre Jean Perrin, Clermont–Ferrand: Yves-Jean Bignon, Nancy Uhrhammer. Centre Léon Bérard, Lyon: Christine Lasset, Valérie Bonadona, Sandrine Handallou. Centre François Baclesse, Caen: Agnès Hardouin, Pascaline Berthet, Dominique Vaur, Laurent Castera. Institut Paoli Calmettes, Marseille: Hagay Sobol, Violaine Bourdon, Tetsuro Noguchi, Audrey Remenieras, François Eisinger. CHU Arnaud-de-Villeneuve, Montpellier: Isabelle Coupier, Pascal Pujol. Centre Oscar Lambret, Lille: Jean-Philippe Peyrat, Joëlle Fournier, Françoise Révillion, Philippe Vennin†, Claude Adenis. Centre Paul Strauss, Strasbourg: Danièle Muller, Jean-Pierre Fricker. Institut Bergonié, Bordeaux: Emmanuelle Barouk-Simonet, Françoise Bonnet, Virginie Bubien, Nicolas Sevenet, Michel Longy. Institut Claudius Regaud, Toulouse: Christine Toulas, Rosine Guimbaud, Laurence Gladieff, Viviane Feillel. CHU Grenoble: Dominique Leroux, Hélène Dreyfus, Christine Rebischung, Magalie Peysselon. CHU Dijon: Fanny Coron, Laurence Faivre. CHU St-Etienne: Fabienne Prieur, Marine Lebrun, Caroline Kientz. Hôtel Dieu Centre Hospitalier, Chambéry: Sandra Fert Ferrer. Centre Antoine Lacassagne, Nice: Marc Frénay. CHU Limoges: Laurence Vénat-Bouvet. CHU Nantes: Capucine Delnatte. CHU Bretonneau, Tours: Isabelle Mortemousque. Groupe Hospitalier Pitié-Salpétrière, Paris: Florence Coulet, Chrystelle Colas, Florent Soubrier, Mathilde Warcoin. CHU Vandoeuvre-les-Nancy: Johanna Sokolowska, Myriam Bronner. CHU Besançon: Marie-Agnès Collonge-Rame, Alexandre Damette. Creighton University, Omaha, USA: Henry T. Lynch, Carrie L. Snyder. (Continues) 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 614 GEORGETOWN CI received support from the Non-Therapeutic Subject Registry Shared Resource at Georgetown University (NIH/NCI grant P30-CA051008), the Fisher Center for Familial Cancer Research, and Swing Fore the Cure. HCBARRETOS This study was supported by Barretos Cancer Hospital, FINEP CT-INFRA (02/2010) and FAPESP (2013/24633-2). We wish to thank members of the Center of Molecular Diagnosis, Oncogenetics Department and Molecular Oncology Research Center of Barretos Cancer Hospital for their contributions to the study. G-FAST Bruce Poppe is a senior clinical investigator of FWO. Mattias Van Heetvelde obtained funding from IWT. We wish to thank the technical support of Ilse Coene en Brecht Crombez. HCSC Was supported by a grant RD12/0036/0006 and 15/00059 from ISCIII (Spain), partially supported by European Regional Development FEDER funds We acknowledge Alicia Tosar and Paula Diaque for their technical assistance HEBCS The HEBCS was financially supported by the Helsinki University Hospital HEBCS would like to thank Taru A. Muranen and Johanna Kiiski, Drs. Research Fund, Academy of Finland (266528), the Finnish Cancer Carl Blomqvist and Kirsimari Aaltonen and RNs Irja Erkkilä and Virpi Society and the Sigrid Juselius Foundation. Palola for their help with the HEBCS data and samples. HEBON The HEBON study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the Netherlands Organisation of Scientific Research grant NWO 91109024, the Pink Ribbon grants 110005 and 2014-187.WO76, the BBMRI grant NWO 184.021.007/CP46 and the Transcan grant JTC 2012 Cancer 12-054. HRBCP HRBCP is supported by The Hong Kong Hereditary Breast Cancer Family We wish to thank Hong Kong Sanatorium and Hospital for their Registry and the Dr. Ellen Li Charitable Foundation, Hong Kong continued support HUNBOCS Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grants KTIA-OTKA CK-80745, NKFIH/ OTKA K-112228 and the Norwegian EEA Financial Mechanism Hu0115/NA/2008-3/OP-9 The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) consists of the following Collaborating Centers: Netherlands Cancer Institute (coordinating center), Amsterdam, NL: M.A. Rookus, F.B.L. Hogervorst, F.E. van Leeuwen, M.A. Adank, M.K. Schmidt, N.S. Russell, J.L. de Lange, R. Wijnands, D.J. Jenner; Erasmus Medical Center, Rotterdam, NL: J.M. Collée, A.M.W. van den Ouweland, M.J. Hooning, C. Seynaeve, C.H.M. van Deurzen, I.M. Obdeijn; Leiden University Medical Center, NL: C.J. van Asperen, J.T. Wijnen, R.A.E.M. Tollenaar, P. Devilee, T.C.T.E.F. van Cronenburg; Radboud University Nijmegen Medical Center, NL: C.M. Kets, A.R. Mensenkamp; University Medical Center Utrecht, NL: M.G.E.M. Ausems, R.B. van der Luijt, C.C. van der Pol; Amsterdam Medical Center, NL: C.M. Aalfs, H.E.J. Meijers-Heijboer, T.A.M. van Os; VU University Medical Center, Amsterdam, NL: K. van Engelen, J.J.P. Gille, Q. Waisfisz; Maastricht University Medical Center, NL: E.B. Gómez-Garcia, M.J. Blok; University of Groningen, NL: J.C. Oosterwijk, A.H. van der Hout, M.J. Mourits, G.H. de Bock; The Netherlands Comprehensive Cancer Organisation (IKNL): S. Siesling, J.Verloop; The nationwide network and registry of histo- and cytopathology in The Netherlands (PALGA): L.I.H. Overbeek. HEBON thanks the study participants and the registration teams of IKNL and PALGA for part of the data collection. We wish to thank the Hungarian Breast and Ovarian Cancer Study Group members (Janos Papp, Tibor Vaszko, Aniko Bozsik, Timea Pocza, Zoltan Matrai, Gabriella Ivady, Judit Franko, Maria Balogh, Gabriella Domokos, Judit Ferenczi, Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary) and the clinicians and patients for their contributions to this study. HVH We wish to thank the Oncogenetics Group (VHIO) and the High Risk and Cancer Prevention Unit of the University Hospital Vall d'Hebron. Acknowledgements to the Cellex Foundation for providing research facilities and equipment. ICO The authors would like to particularly acknowledge the support of the We wish to thank the ICO Hereditary Cancer Program team led by Dr. Asociación Española Contra el Cáncer (AECC), the Instituto de Salud Gabriel Capella. Carlos III (organismo adscrito al Ministerio de Economía y Competitividad) and “Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa” (PI10/01422, PI13/00285, PIE13/00022, PI15/00854, PI16/00563 and CIBERONC) and the Institut Català de la Salut and Autonomous Government of Catalonia (2009SGR290, 2014SGR338 and PERIS Project MedPerCan).ICO: Contract grant sponsor: Asociación Española Contra el Cáncer, Spanish Health Research Fund; Carlos III Health Institute; Catalan Health Institute and Autonomous Government of Catalonia. Contract grant numbers: ISCIIIRETIC RD06/0020/1051, RD12/0036/008, PI10/01422, PI10/00748, PI13/00285, PIE13/00022, 2009SGR290 and 2014SGR364. (Continues) 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 615 REBBECK ET AL . REBBECK ET AL . IHCC The IHCC was supported by Grant PBZ_KBN_122/P05/2004 ILUH The ILUH group was supported by the Icelandic Association “Walking for Breast Cancer Research” and by the Landspitali University Hospital Research Fund. INHERIT This work was supported by the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program, the Canadian Breast Cancer Research Alliance-grant #019511 and the Ministry of Economic Development, Innovation and Export Trade – grant # PSR-SIIRI-701. IOVCHBOCS IOVCHBOCS is supported by Ministero della Salute and “5 × 1000” Istituto Oncologico Veneto grant. IPOBCS This study was in part supported by Liga Portuguesa Contra o Cancro. We wish to thank Drs. Catarina Santos, Patrícia Rocha and Pedro Pinto for their skillful contribution to the study. KCONFAB kConFab is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia; Amanda Spurdle is supported by an NHMRC Senior Research Fellowship. We wish to thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (which has received funding from the NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the National Institute of Health (USA)) for their contributions to this resource, and the many families who contribute to kConFab. KOHBRA KOHBRA is partially supported by a grant from the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea (1020350 & 1420190). MAYO MAYO is supported by NIH grants CA116167, CA128978 and CA176785, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a grant from the Breast Cancer Research Foundation, and a generous gift from the David F. and Margaret T. Grohne Family Foundation. MCGILL Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry of Economic Development, Innovation and Export Trade MODSQUAD MODSQUAD was supported by MH CZ - DRO (MMCI, 00209805) and by Modifier Study of Quantitative Effects on Disease (MODSQUAD): the project MEYS-NPS I- LO1413, and by Charles University in Prague MODSQUAD acknowledges ModSQuaD members and Michal Zikan, project UNCE204024 (MZ). Petr Pohlreich and Zdenek Kleibl (Oncogynecologic Center and Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic). MUV MSKCC We wish to thank Daniela Muhr and the Senology team, and the clinicians and patients for their contributions to this study. MSKCC is supported by grants from the Breast Cancer Research Foundation, the Robert and Kate Niehaus Clinical Cancer Genetics Initiative, the Andrew Sabin Research Fund. and the NIH/NCI Cancer Center Support Grant P30 CA008748. MUV Dr J Ngeow is supported by grants from National Medical Research Council of Singapore; Ministry of Health Health Services Research Grant Singapore and Lee Foundation Singapore NCI The research of Drs. MH Greene, PL Mai, and JT Loud was supported by the Intramural Research Program of the US National Cancer Institute, NIH, and by support services contracts NO2-CP-11019-50 and N02-CP-65504 with Westat, Inc, Rockville, MD. NNPIO This work has been supported by the Russian Federation for Basic Research (grants 14-04-93959 and 15-04-01744). NRG Oncology OCGN Anne Lincoln, Lauren Jacobs We wish to thank Daniela Muhr and the Senology team, and the clinicians and patients for their contributions to this study. NCCS Northshore We would like to thank Dr Martine Dumont, Martine Tranchant for sample management and skillful technical assistance. J.S. is Chairholder of the Canada Research Chair in Oncogenetics. J.S. was part of the QC and Genotyping coordinating group of iCOGS (BCAC and CIMBA). We would like to thank all patients, families and clinicians who contributed data and time to this study. We would like to thank Wendy Rubinstein and the following genetic counselors for help with participant recruitment: Scott Weissman, Anna Newlin, Kristen Vogel, Lisa Dellafave-Castillo, Shelly Weiss. This study was supported by NRG Oncology Operations grant number We thank the investigators of the Australia New Zealand NRG U10 CA180868 as well as NRG SDMC grant U10 CA180822, Oncology group Gynecologic Oncology Group (GOG) Administrative Office and the GOG Tissue Bank (CA 27469) and the GOG Statistical and Data Center (CA 37517). Drs. Greene, Mai and Loud were supported by funding from the Intramural Research Program, NCI. We wish to thank members and participants in the Ontario Cancer Genetics Network for their contributions to the study. (Continues) 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 616 OSUCCG OSUCCG is supported by the Ohio State University Comprehensive Cancer Center. PBCS This work was supported by the ITT (Istituto Toscano Tumori) grants 2011–2013. SEABASS Ministry of Science, Technology and Innovation, Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer Research Initiatives Foundation We would like to thank Yip Cheng Har, Nur Aishah Mohd Taib, Phuah Sze Yee, Norhashimah Hassan and all the research nurses, research assistants and doctors involved in the MyBrCa Study for assistance in patient recruitment, data collection and sample preparation. In addition, we thank Philip Iau, Sng Jen-Hwei and Sharifah Nor Akmal for contributing samples from the Singapore Breast Cancer Study and the HUKM-HKL Study respectively. The Malaysian Breast Cancer Genetic Study is funded by research grants from the Malaysian Ministry of Science, Technology and Innovation, Ministry of Higher Education (UM.C/HIR/MOHE/06) and charitable funding from Cancer Research Initiatives Foundation. SMC This project was partially funded through a grant by the Israel cancer association and the funding for the Israeli Inherited breast cancer consortium SMC team wishes to acknowledge the assistance of the Meirav Comprehensive breast cancer center team at the Sheba Medical Center for assistance in this study. SWE-BRCA SWE-BRCA collaborators are supported by the Swedish Cancer Society Swedish scientists participating as SWE-BRCA collaborators are: from Lund University and University Hospital: Åke Borg, Håkan Olsson, Helena Jernström, Karin Henriksson, Katja Harbst, Maria Soller, Ulf Kristoffersson; from Gothenburg Sahlgrenska University Hospital: Margareta Nordling, Per Karlsson, Zakaria Einbeigi; from Stockholm and Karolinska University Hospital: Annika Lindblom, Brita Arver, Gisela Barbany Bustinza, Johanna Rantala; from Umeå University Hospital: Beatrice Melin, Christina Edwinsdotter Ardnor, Monica Emanuelsson; from Uppsala University: Maritta Hellström Pigg, Richard Rosenquist; from Linköping University Hospital: Marie Stenmark-Askmalm, Sigrun Liedgren UCHICAGO UCHICAGO is supported by NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA125183), R01 CA142996, 1U01CA161032 and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund National Women's Cancer Research Alliance and the Breast Cancer research Foundation. OIO is an ACS Clinical Research Professor. We wish to thank Cecilia Zvocec, Qun Niu, physicians, genetic counselors, research nurses and staff of the Cancer Risk Clinic for their contributions to this resource, and the many families who contribute to our program. UCLA Jonsson Comprehensive Cancer Center Foundation; Breast Cancer Research Foundation We thank Joyce Seldon MSGC and Lorna Kwan, MPH for assembling the data for this study. UCSF UCSF Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center We would like to thank the following genetic counselors for participant recruitment: Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, and Peggy Conrad. And thanks to Ms. Salina Chan for her data management. UKFOCR UKFOCR was supported by a project grant from CRUK to Paul Pharoah. We thank Simon Gayther, Carole Pye, Patricia Harrington and Eva Wozniak for their contributions toward the UKFOCR. UPENN National Institutes of Health (NIH) (R01-CA102776 and R01-CA083855; Breast Cancer Research Foundation; Susan G. Komen Foundation for the cure, Basser Research Center for BRCA UPITT/MWH Frieda G. and Saul F. Shapira BRCA-Associated Cancer Research Program; Hackers for Hope Pittsburgh VFCTG Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation WCP Beth Y. Karlan was supported by the American Cancer Society Early Detection Professorship (SIOP-06-258-06-COUN) and the National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000124 REFERENCES Abugattas, J., Llacuachaqui, M., Allende, Y. S., Velásquez, A. A., Velarde, R., Cotrina, J., … Narod, S. A. (2015). Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clinical Genetics, 88(4), 371–375. Ah Mew, N., Hamel, N., Galvez, M., Al-Saffar, M., & Foulkes, W. D. (2002). Haplotype analysis of a BRCA1: 185delAG mutation in a Chilean family supports its Ashkenazi origins. Clinical Genetics, 62(2), 151–156. Kevin Sweet, Caroline Craven, Julia Cooper, and Michelle O'Conor were instrumental in accrual of study participants, ascertainment of medical records and database management. Geoffrey Lindeman, Marion Harris, Martin Delatycki of the Victorian Familial Cancer Trials Group. We thank Sarah Sawyer and Rebecca Driessen for assembling this data and Ella Thompson for performing all DNA amplification. Ahn, S. H., Son, B. H., Yoon, K. S., Noh, D. Y., Han, W., Kim, S. W., … Cho, D. Y. (2007). BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Letters, 245(1-2), 90– 95. Alemar, B., Herzog, J., Brinckmann, O. N. C., Artigalás, O., Schwartz, I. V. D., Matzenbacher Bittar, C., … Weitzel, J. N. (2016). Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 617 REBBECK ET AL . REBBECK ET AL . among Latin American populations. Cancer Genetics, 209(9), 417– 422. BRCA1 gene in ovarian cancer families from Russia. American Journal of Human Genetics, 60(5), 1239–1242. Anczukow, O., Ware, M. D., Buisson, M., Zetoune, A. B., Stoppa-Lyonnet, D., Sinilnikova, O. M., & Mazoyer, S. (2008). Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Human Mutation, 29(1), 65–73. Gayther, S. A., Mangion, J., Russell, P., Seal, S., Barfoot, R., Ponder, B. A., … Easton, D. (1997). Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature Genetics, 15(1), 103–105. Antoniou, A. C., Sinilnikova, O. M., Simard, J., Léoné, M., Dumont, M., Neuhausen, S. L., … Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2007). RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: Results from a combined analysis of 19 studies. American Journal of Human Genetics, 81(6), 1186–1200. Gayther, S. A., Warren, W., Mazoyer, S., Russell, P. A., Harrington, P. A., Chiano, M., … Dunning, A. M. (1995). Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genetics, 11(4), 428–433. Bergthorsson, J. T., Jonasdottir, A., Johannesdottir, G., Arason, A., Egilsson, V., Gayther, S., … Barkardottir, R. B. (1998). Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: Screening reveals low frequency in Icelandic breast cancer patients. Human Mutation Suppl, 1, S195–7. Goldgar, D. E., Easton, D. F., Deffenbaugh, A. M., Monteiro, A. N., Tavtigian, S. V., & Couch, F. J. (2004). Integrated evaluation of DNA sequence variants of unknown clinical significance: Application to BRCA1 and BRCA2. American Journal of Human Genetics, 75(4), 535–544. Bernstein, J. L., Teraoka, S., Southey, M. C., Jenkins, M. A., Andrulis, I. L., Knight, J. A., … Concannon, P. (2006). Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the breast cancer family registry. Human Mutation, 27(11), 1122–1128. Bu, R., Siraj, A. K., Al-Obaisi, K. A., Beg, S., Al Hazmi, M., Ajarim, D., … Al-Kuraya, K. S. (2016). Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis. International Journal of Cancer, 139(5), 1091–1097. Buisson, M., Anczukow, O., Zetoune, A. B., Ware, M. D., & Mazoyer, S. (2006). The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat, 27(10), 1024–1029. Chen, S., & Parmigiani, G. (2007). Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology, 25(11), 1329–1333. Gonzalez-Hormazabal, P., Gutierrez-Enriquez, S., Gaete, D., Reyes, J. M., Peralta, O., Waugh, E., … Jara, L. (2011). Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families. Breast Cancer Research and Treatment, 126(3), 705–716. Gorski, B., Byrski, T., Huzarski, T., Jakubowska, A., Menkiszak, J., Gronwald, J., … Lubiński, J. (2000). Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. American Journal of Human Genetics, 66(6), 1963–1968. Hamel, N., Feng, B. J., Foretova, L., Stoppa-Lyonnet, D., Narod, S. A., Imyanitov, E., … Foulkes, W. D. (2011). On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. European Journal of Human Genetics, 19(3), 300–306. Hansen, T. V., Ejlertsen, B., Albrechtsen, A., Bergsten, E., Bjerregaard, P., Hansen, T., … Nielsen, F. C. (2009). A common Greenlandic Inuit BRCA1 RING domain founder mutation. Breast Cancer Research and Treatment, 115(1), 69–76. Chenevix-Trench, G., Milne, R. L., Antoniou, A. C., Couch, F. J., Easton, D. F., & Goldgar, D. E. (2007). An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: The consortium of investigators of modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Research, 9(2), 104. Ho, G. H., Phang, B. H., Ng, I. S., Law, H. Y., Soo, K. C., & Ng, E. H. (2000). Novel germline BRCA1 mutations detected in women in singapore who developed breast carcinoma before the age of 36 years. Cancer, 89(4), 811– 816. Cock-Rada, A. M., Ossa, C. A., Garcia, H. I., & Gomez, L. R. 2017. A multigene panel study in hereditary breast and ovarian cancer in Colombia. Familial Cancer, 17(1), 23–30 Jara, L., Ampuero, S., Santibanez, E., Seccia, L., Rodriguez, J., Bustamante, M., … Reyes, J. M. (2006). BRCA1 and BRCA2 mutations in a South American population. Cancer Genetics and Cytogenetics, 166(1), 36–45. Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., … Rebbeck, T. R. (2010). Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality. Jama-Journal of the American Medical Association, 304(9), 967–975. John, E. M., Miron, A., Gong, G., Phipps, A. I., Felberg, A., Li, F. P., … Whittemore, A. S. (2007). Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. Journal of the American Medical Association, 298(24), 2869–2876. Eachkoti, R., Hussain, I., Afroze, D., Aejazaziz, S., Jan, M., Shah, Z. A., … Siddiqi, M. A. (2007). BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. Cancer Letters, 248(2), 308–320. Kadalmani, K., Deepa, S., Bagavathi, S., Anishetty, S., Thangaraj, K., & Gajalakshmi, P. (2007). Independent origin of 185delAG BRCA1 mutation in an Indian family. Neoplasma, 54(1), 51–56. Ferla, R., Calo, V., Cascio, S., Rinaldi, G., Badalamenti, G., Carreca, I., … Russo, A. (2007). Founder mutations in BRCA1 and BRCA2 genes. Annals of Oncology, 18(Suppl 6), vi93–8. Friedman, E., Bar-Sade Bruchim, R., Kruglikova, A., Risel, S., Levy-Lahad, E., Halle, D., … Abeliovich, A. D. (1998). Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. American Journal of Human Genetics, 63(4), 1224–1227. Gao, Q., Tomlinson, G., Das, S., Cummings, S., Sveen, L., Fackenthal, J., … Olopade, O. I. (2000). Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Human Genetics, 107(2), 186–191. Gayther, S. A., Harrington, P., Russell, P., Kharkevich, G., Garkavtseva, R. F., & Ponder, B. A. (1997). Frequently occurring germ-line mutations of the Kaufman, B., Laitman, Y., Gronwald, J., Lubinski, J., & Friedman, E. (2009). Haplotype of the C61G BRCA1 mutation in Polish and Jewish individuals. Genetic Testing and Molecular Biomarkers, 13(4), 465–469. Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M., Roos-Blom, M. J., … Olsson, H. (2017). Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Journal of the American Medical Association, 317(23), 2402–2416. Kurian, A. W. (2010). BRCA1 and BRCA2 mutations across race and ethnicity: Distribution and clinical implications. Current Opinion in Obstetrics Gynecology, 22(1), 72–78. Laitman, Y., Borsthein, R. T., Stoppa-Lyonnet, D., Dagan, E., Castera, L., Goislard, M., … Friedman, E. (2011). Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Research and Treatment, 127(2), 489–495. 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 618 Laitman, Y., Feng, B. J., Zamir, I. M., Weitzel, J. N., Duncan, P., Port, D., … Friedman, E. (2013). Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. European Journal of Human Genetics, 21(2), 212–216. Lang, G. T., Shi, J. X., Hu, X., Zhang, C. H., Shan, L., Song, C. G., … Shao, Z. M. (2017). The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. International Journal of Cancer, 141(1), 129–142. Lee, A. S., Ho, G. H., Oh, P. C., Balram, C., Ooi, L. L., Lim, D. T., … Hong, G. S. (2003). Founder mutation in the BRCA1 gene in Malay breast cancer patients from Singapore. Human Mutation, 22(2), 178. Li, N., Zhang, X., Cai, Y., Xu, X., Zhang, L., Pan, K. F., … Wang, M. R. (2006). BRCA1 germline mutations in Chinese patients with hereditary breast and ovarian cancer. International Journal of Gynecological Cancer, 16(Suppl 1):172–178. Lord, C. J., & Ashworth, A. (2017). PARP inhibitors: Synthetic lethality in the clinic. Science, 355(6330), 1152–1158. Maxwell, K. N., Domchek, S. M., Nathanson, K. L., & Robson, M. E. (2016). Population Frequency of Germline BRCA1/2 Mutations. Journal of Clinical Oncology, 34(34), 4183–4185. Mikaelsdottir, E. K., Valgeirsdottir, S., Eyfjord, J. E., & Rafnar, T. (2004). The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Res 6(4), R284–R290. Moslehi, R., Russo, D., Phelan, C., Jack, E., Antman, K., & Narod, S. (2000). An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2. Clinical Genetics, 57(1), 70–73. Nanda, R., Schumm, L. P., Cummings, S., Fackenthal, J. D., Sveen, L., Ademuyiwa, F., … Olopade, O. I. (2005). Genetic testing in an ethnically diverse cohort of high-risk women: A comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. Journal of the American Medical Association, 294(15), 1925– 1933. NCCN. (2017). Updates in version 2.2017 of the NCCN guidelines for genetic/familial high-risk assessment: Breast and ovarian cancer. Neuhausen, S. L., Godwin, A. K., Gershoni-Baruch, R., Schubert, E., Garber, J., Stoppa-Lyonnet, D., … Goldgar, D. (1998). Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: Results of an international study. American Journal of Human Genetics, 62(6), 1381– 1388. Neuhausen, S. L., Mazoyer, S., Friedman, L., Stratton, M., Offit, K., Caligo, A., … Goldgar, D. E. (1996). Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: Results of an international study. American Journal of Human Genetics, 58(2), 271–280. Oros, K. K., Ghadirian, P., Maugard, C. M., Perret, C., Paredes, Y., MesMasson, A. M., … Tonin, P. N. (2006a). Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. Clinical Genetics, 70(4), 320–329. Oros, K. K., Leblanc, G., Arcand, S. L., Shen, Z., Perret, C., Mes-Masson, A. M., … Tonin, P. N. (2006b). Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Medical Genetics, 7, 23. 619 Pal, T., Permuth-Wey, J., Holtje, T., & Sutphen, R. (2004). BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. Cancer Epidemiology, Biomarkers & Prevention, 13(11 Pt 1), 1794–1799. Palomba, G., Cossu, A., Friedman, E., Budroni, M., Farris, A., Contu, A., … Palmieri, G. (2007). Origin and distribution of the BRCA2-8765delAG mutation in breast cancer. BMC Cancer, 7(1), 132. Perrin-Vidoz, L., Sinilnikova, O. M., Stoppa-Lyonnet, D., Lenoir, G. M., & Mazoyer, S. (2002). The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Human Molecular Genetics, 11(23), 2805–2814. Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., … Stratton, M. R. (1999). Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. Journal of National Cancer Institute, 91(11), 943–949. Pisano, M., Cossu, A., Persico, I., Palmieri, G., Angius, A., Casu, G., … Tanda, F. (2000). Identification of a founder BRCA2 mutation in Sardinia. British Journal of Cancer, 82(3), 553–559. Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., … Nelson, P. S. (2016). Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England Journal of Medicine, 375(5), 443–453. Ramus, S. J., Friedman, L. S., Gayther, S. A., Ponder, B. A., Bobrow, L., van der Looji, M., … Olah, E. (1997a). A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. Nature Genetics, 15(1), 14–15. Ramus, S. J., Kote-Jarai, Z., Friedman, L. S., van der Looij, M., Gayther, S. A., Csokay, B., … Olah, E. (1997b). Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. American Journal of Human Genetics, 60(5), 1242–1246. Rashid, M. U., Zaidi, A., Torres, D., Sultan, F., Benner, A., Naqvi, B., … Hamann, U. (2006). Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. International Journal of Cancer, 119(12), 2832–2839. Rebbeck, T. R., Friebel, T. M., Mitra, N., Wan, F., Chen, S., Andrulis, I. L., … Ramus, S. J. (2016). Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 18(1), 112. Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Van't Veer, L., Garber, J. E., … Prevention and Observation of Surgical End Points Study Group (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. The New England Journal of Medicine, 346(21), 1616–1622. Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., … Andrulis, I. (2015). Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. Journal of the American Medical Association, 313(13), 1347–1361. Reeves, M. D., Yawitch, T. M., van der Merwe, N. C., van den Berg, H. J., Dreyer, G., & van Rensburg, E. J. (2004). BRCA1 mutations in South African breast and/or ovarian cancer families: Evidence of a novel founder mutation in Afrikaner families. International Journal of Cancer, 110(5), 677–682. Roa, B. B., Boyd, A. A., Volcik, K., & Richards, C. S. (1996). Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics, 14(2), 185–187. Ossa, C. A., & Torres, D. (2016). Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review. Oncologist, 21(7), 832–839. Rodríguez, A. O., Llacuachaqui, M., Pardo, G. G., Royer, R., Larson, G., Weitzel, J. N., & Narod, S. A. (2012). BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecologic Oncology, 124(2), 236–243. Ostrander, E. A., & Udler, M. S. (2008). The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiology Biomarkers & Prevention, 17(8), 1843–1848. Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., … American Cancer Society Breast CancerAdvisory Group (2007). American Cancer Society guidelines for breast screening with MRI as an 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License REBBECK ET AL . adjunct to mammography. CA: A Cancer Journal for Clinicians, 57(2), 75– 89. Seong, M. W., Cho, S., Noh, D. Y., Han, W., Kim, S. W., Park, C. M., … Park, S. S. (2009). Comprehensive mutational analysis of BRCA1/BRCA2 for Korean breast cancer patients: Evidence of a founder mutation. Clinical Genetics, 76(2), 152–160. Sharifah, N. A., Nurismah, M. I., Lee, H. C., Aisyah, A. N., Clarence-Ko, C. H., Naqiyah, I., … Nor Hisham, A. (2010). Identification of novel large genomic rearrangements at the BRCA1 locus in Malaysian women with breast cancer. Cancer Epidemiology, 34(4), 442–447. Solano, A. R., Cardoso, F. C., Romano, V., Perazzo, F., Bas, C., Recondo, G., … Mando, O. G. (2017). Spectrum of BRCA1/2 variants in 940 patients from Argentina including novel, deleterious and recurrent germline mutations: Impact on healthcare and clinical practice. Oncotarget, 8(36), 60487–60495. Song, C. G., Hu, Z., Yuan, W. T., Di, G. H., Shen, Z. Z., Huang, W., & Shao, Z. M. (2005). [Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai]. Zhonghua Yi Xue Za Zhi, 85(43), 3030–3034. Song, C. G., Hu, Z., Yuan, W. T., Di, G. H., Shen, Z. Z., Huang, W., & Shao, Z. M. (2006). [BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 23(1), 27– 31. Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., … Tucker, M. A. (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. The New England Journal of Medicine, 336(20), 1401–1408. Thompson, E. R., Rowley, S. M., Li, N., McInerny, S., Devereux, L., WongBrown, M. W., … Campbell, I. G. (2016). Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. Journal of Clinical Oncology, 34(13), 1455–1459. Thorlacius, S., Olafsdottir, G., Tryggvadottir, L., Neuhausen, S., Jonasson, J. G., Tavtigian, S. V., … Eyfjord, J. E. (1996). A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nature Genetics, 13(1), 117–119. Toh, G. T., Kang, P., Lee, S. S., Lee, D. S., Lee, S. Y., Selamat, S., … Teo, S. H. (2008). BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. Public Library of Science ONE, 3(4), e2024. Tonin, P. M., Mes-Masson, A. M., Narod, S. A., Ghadirian, P., & Provencher, D. (1999). Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clinical Genetics, 55(5), 318–324. Tonin, P. N., Perret, C., Lambert, J. A., Paradis, A. J., Kantemiroff, T., Benoit, M. H., … Ghadirian, P. (2001). Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history. International Journal of Cancer, 95(3), 189–193. Torres, D., Rashid, M. U., Gil, F., Umana, A., Ramelli, G., Robledo, J. F., … Hamann, U. (2007). High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Research and Treatment, 103(2), 225–232. Troudi, W., Uhrhammer, N., Sibille, C., Dahan, C., Mahfoudh, W., Bouchlaka Souissi, C., … Ben Ammar Elgaaied, A. (2007). Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia. Journal of Human Genetics, 52(11), 915–920. van Der Looij, M., Wysocka, B., Brozek, I., Jassem, J., Limon, J., & Olah, E. (2000). Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Human Mutation 15(5), 480–481. REBBECK ET AL . Velez, C., Palamara, P. F., Guevara-Aguirre, J., Hao, L., Karafet, T., GuevaraAguirre, M., … Ostrer, H. (2012). The impact of Converso Jews on the genomes of modern Latin Americans. Human Genetics, 131(2), 251–263. Villarreal-Garza, C., Alvarez-Gómez, R. M., Pérez-Plasencia, C., Herrera, L. A., Herzog, J., Castillo, D., … Weitzel, J. N. (2015a). Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer, 121(3), 372–378. Villarreal-Garza, C., Weitzel, J. N., Llacuachaqui, M., Sifuentes, E., Magallanes-Hoyos, M. C., Gallardo, L., … Narod, S. A. (2015b). The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. Breast Cancer Reserach and Treatment, 150(2), 389–394. Vogel, K. J., Atchley, D. P., Erlichman, J., Broglio, K. R., Ready, K. J., Valero, V., … Arun, B. (2007). BRCA1 and BRCA2 genetic testing in Hispanic patients: Mutation prevalence and evaluation of the BRCAPRO risk assessment model. Journal of Clinical Oncology, 25(29), 4635– 4641. Ware, M. D., DeSilva, D., Sinilnikova, O. M., Stoppa-Lyonnet, D., Tavtigian, S. V. & Mazoyer, S. (2006). Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene? Oncogene, 25(2), 323–328. Weitzel, J. N., Clague, J., Martir-Negron, A., Ogaz, R., Herzog, J., Ricker, C., … Larson, G. P. (2013). Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: A report from the Clinical Cancer Genetics Community Research Network. Journal of Clinical Oncology, 31(2), 210–216. Weitzel, J. N., Lagos, V., Blazer, K. R., Nelson, R., Ricker, C., Herzog, J., … Neuhausen, S. (2005). Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiology, Biomarkers & Prevention, 14(7), 1666–1671. Weitzel, J. N., Lagos, V. I., Herzog, J. S., Judkins, T., Hendrickson, B., Ho, J. S., … Scholl, T. (2007). Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk hispanic families. Cancer Epidemiology, Biomarkers & Prevention, 16(8), 1615– 1620. Welcsh, P. L., & King, M. C. (2001). BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Human Molecular Genetics, 10(7), 705–713. Whittemore, A. S., Gong, G., John, E. M., McGuire, V., Li, F. P., Ostrow, K. L., … West, D. W. (2004). Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiology, Biomarkers & Prevention, 13(12), 2078–2083. Zhang, B., Fackenthal, J. D., Niu, Q., Huo, D., Sveen, W. E., DeMarco, T., … Olopade, O. I. (2009). Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Familial Cancer, 8(1), 15–22. SUPPORTING INFORMATION Additional Supporting Information may be found online in the supporting information tab for this article. How to cite this article: Rebbeck TR, Friebel TM, Friedman E, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Human Mutation. 2018;39:593–620. https://doi.org/10.1002/humu.23406 10981004, 2018, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/humu.23406 by Uva Universiteitsbibliotheek, Wiley Online Library on [24/10/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License 620